Filings

●What changed:Cayson Acquisition Corp filed a DEF 14A for an Extraordinary General Meeting on September 23, 2026, to vote on extending the business combination deadline to September 23, 2027, following the mutual termination of its definitive agreement with Mango Financial Group Limited on September 2, 2026. The filing sets a redemption deadline of 5:00 p.m. Eastern Time on September 21, 2026, and estimates a per-share redemption price of approximately $11.22 based on a Trust Account balance of approximately $38.8 million as of August 31, 2026. Why it matters: Investors must decide by September 21 whether to redeem shares at the estimated $11.22 price or retain them to vote on the extension; failure to approve the extension or complete a deal by the current deadline triggers liquidation.

●What changed:IB Acquisition Corp. filed a DEF 14A proposing to extend its business combination deadline from September 28, 2026, to March 28, 2027, via a special meeting on September 24, 2026; the filing details redemption rights for public shares at approximately $10.93 per share based on a Trust Account balance of approximately $8.3 million as of the August 27, 2026 record date. Why it matters: Investors must vote by September 22, 2026, to redeem their shares or face continued exposure to extension risks and potential Nasdaq delisting if redemptions reduce stockholders' equity below listing requirements.

●What changed:Spark I Acquisition Corp filed a Definitive Proxy Statement for an Extraordinary General Meeting on September 25, 2026, to vote on extending the business combination deadline from September 29, 2026, to March 29, 2027. The filing estimates a redemption price of approximately $11.60 per share based on a Trust Account balance of $25,959,052 and details a Second Extension Contribution of up to $201,304 from Sponsor SLG SPAC Fund LLC. Why it matters: Investors must decide by September 23, 2026, whether to redeem shares at the estimated $11.60 premium or retain them for the ZincFive merger; failure to approve the extension triggers liquidation by September 29, 2026, with warrants expiring worthless.

What changed:The filing is a Definitive Proxy Statement (DEF 14A) for Profusa, Inc. regarding a Special Meeting of Stockholders scheduled for September 18, 2026. The document details two proposals: (1) A Reverse Stock Split Proposal to amend the Certificate of Incorporation to allow the Board to effect one or more reverse stock splits at a ratio of 1-for-2 to 1-for-12 over the next two years (prior to or on September 18, 2028), with an aggregate limit of 1-for-12; and (2) An Adjournment Proposal to authorize adjourning the meeting to solicit additional proxies if necessary. The filing discloses that Profusa has already effected three reverse stock splits in 2026: a 1-for-75 split on February 9, 2026; a 1-for-25 split on July 7, 2026; and a 1-for-4 split on August 17, 2026. The Company states it is seeking this new authority to regain compliance with Nasdaq’s Minimum Bid Price Requirement ($1.00 per share) and Publicly Held Shares Rule after inadvertently falling below the latter during the August split. As of the record date (August 19, 2026), there were 605,647 shares of common stock outstanding. Why it matters: This filing is critical for investors because it outlines the company's ongoing struggle to maintain its Nasdaq listing due to repeated non-compliance with bid price and public float requirements. The history of multiple aggressive reverse splits (totaling up to 1-for-600 combined) indicates severe distress and potential liquidity issues. The current proposal grants the Board broad discretion to further dilute share count via future splits without additional shareholder approval, which may depress the stock price or lead to odd-lot transaction costs for small holders. Furthermore, the filing confirms the company remains subject to delisting risks, which could impair its ability to raise capital through S-3 shelf eligibility or its Equity Line of Credit, threatening its operational viability.

What changed:The filing is a Definitive Proxy Statement (DEF 14A) for Citius Oncology, Inc. regarding its 2026 Annual Meeting of Stockholders scheduled for September 29, 2026. It does not contain SPAC redemption deadlines or trust value updates as the SPAC TenX Keane Acquisition status is CLOSED; instead, it reports on corporate governance and executive compensation matters. Key disclosures include: 1) Election of three Class II directors (Dr. Eugene Holuka, Robert Smith, Carol Webb) to serve until the 2029 Annual Meeting. 2) Ratification of Wolf Company, P.C. as the independent auditor for the fiscal year ending September 30, 2026. 3) Executive compensation details for Named Executive Officers Leonard Mazur, Myron Holubiak, and Myron Czuczman, including base salaries ($166,250 for Mazur; $450,000 for Holubiak; $225,000 for Czuczman in FY2025) and equity awards valued at $2,975,000, $1,487,500, and $1,443,750 respectively. 4) A related-party transaction update regarding an unsecured promissory note from Citius Pharma, amended on May 4, 2026, to change maturity triggers to require $50 million in gross proceeds or senior debt repayment, with a voluntary conversion feature at $0.90 per share. 5) Security ownership data showing Citius Pharmaceuticals, Inc. holds 71.0% of outstanding shares as of August 17, 2026. Why it matters: Investors tracking sponsor conduct and deal progress should note that while the SPAC shell is closed, the operating company (Citius Oncology) continues to manage significant related-party dependencies, evidenced by the amended promissory note terms which tie repayment to future capital raises or monetization events. The proxy statement confirms board continuity and auditor retention, but highlights high insider ownership concentration (71.0% by Citius Pharma) and substantial equity-based compensation for executives, which may impact shareholder dilution and alignment of interests. The filing provides the specific record date (August 17, 2026) and voting procedures for the upcoming annual meeting, which is the primary mechanism for shareholder oversight in this closed-SPAC structure.

What changed:WinVest Acquisition Corp. filed its definitive proxy statement (DEF 14A) on August 25, 2026, scheduling a virtual special stockholder meeting for September 15, 2026 at 11:00 a.m. Eastern Time. The company is seeking stockholder approval for three proposals: (1) an Extension Amendment Proposal to amend the Certificate of Incorporation to extend the Termination Date from September 17, 2026 to October 17, 2026, with up to five additional one-month extensions at the Sponsor's request, extending no later than March 17, 2027; (2) a Trust Amendment Proposal to amend the Investment Management Trust Agreement with Continental Stock Transfer & Trust Company to extend the Liquidation Date on the same timeline; and (3) an Adjournment Proposal. The stated purpose is to allow additional time to consummate the previously announced Business Combination with Embed Financial Group Cayman Holdings, which was entered into on December 2, 2025. Per the terms, if the proposals are approved, the Sponsor (or its designee) will lend the company $30,000 per extension month via a non-interest-bearing, unsecured promissory note (up to $180,000 total), to be deposited into the Trust Account. If the Business Combination is completed, the note will be repaid; if not, it will be repaid only from funds outside the Trust Account or forfeited. The record date for voting is August 19, 2026, with 3,133,251 shares of Common Stock outstanding (258,251 Public Stock and 2,875,000 Founder Shares). The Initial Stockholders hold 91.8% of outstanding Common Stock and intend to vote in favor, meaning no Public Stock votes are required for approval. The Board unanimously recommends voting FOR all three proposals. Why it matters: This is an extension vote, not a business combination vote. The redemption deadline is 5:00 p.m. Eastern Time on September 13, 2026 (two business days before the September 15, 2026 stockholder meeting). Public stockholders may redeem shares for their pro rata portion of the Trust Account regardless of how they vote. The redemption price per share is approximately $15.16 as of August 25, 2026, based on approximately $3,122,654 in the Trust Account divided by outstanding Public Stock shares. The closing price of Public Stock on the OTC Markets on August 24, 2026 was $12.55 per share, meaning redemption would yield approximately $2.61 more per share than selling on the open market. WinVest was delisted from Nasdaq on March 20, 2025 after failing to complete a business combination by the Panel's March 17, 2025 deadline; its securities now trade on OTC Markets under tickers WINV, WINVR, WINVU, and WINVW. The Trust Account currently holds cash in an interest-bearing bank account at approximately 3.25% per annum (liquidated from U.S. government securities to avoid Investment Company Act regulation). The company has issued unsecured promissory notes in the aggregate principal amount of $4.22 million to the Sponsor. If the extension proposals fail and the Business Combination is not completed by September 17, 2026, the company will liquidate, redeem Public Stock at the pro rata Trust Account value, and warrants and rights will expire worthless. The Initial Stockholders have waived their right to participate in any liquidation distribution with respect to their 2,875,000 Founder Shares.

What changed:YHN Acquisition I Ltd filed a Definitive Proxy Statement (DEF 14A) on August 24, 2026, soliciting shareholder votes for an Annual Meeting on September 14, 2026. The filing proposes two amendments to extend the Company's deadline to consummate a business combination from September 19, 2026, to June 19, 2027, in three-month increments. If approved, the Sponsor will contribute $100,000 per extension as an interest-free loan repayable upon business combination completion or forgiven if liquidation occurs. The filing states that approximately $27,968,729.26 was in the Trust Account as of August 20, 2026, yielding an estimated redemption price of $11.03 per share. It also discloses that 3,464,179 shares were tendered for redemption at the previous meeting and details a prior Business Combination Agreement with Mingde Technology Limited entered into on April 3, 2025. Why it matters: This filing establishes the critical redemption deadline of September 10, 2026, for shareholders seeking to exit at the pro rata trust value before any potential extension takes effect. It confirms the specific cost ($100,000 per extension) and mechanism (Sponsor loans) for extending the SPAC's life, directly impacting the timeline for investors to realize returns or face liquidation. The disclosure of the Mingde Technology agreement provides context for the ongoing search for a target, while the redemption price estimate allows investors to compare the cash-out option against market trading prices.

●What changed:Integrated Wellness Acquisition Corp filed a DEF 14A for an extraordinary general meeting on September 15, 2026, to vote on extending the business combination deadline from September 16, 2026, to March 16, 2027. The filing details redemption rights at approximately $13.19 per share based on June 30, 2026 trust balances of $0.94 million, and confirms the target is Btab Ecommerce Group, Inc., with shareholder approval already obtained in December 2025. Why it matters: Investors must decide by September 15, 2026, whether to redeem shares for ~$13.19 or hold for the extended timeline to complete the Btab merger; failure to extend results in liquidation and redemption at the then-current trust value.

●What changed:OneMedNet Corporation filed its definitive proxy for the 2026 annual meeting, to be held online on September 18, 2026 at 11:00 a.m. Central Time, record date August 11, 2026. The proposals are: election of three Class III directors to three-year terms; ratification of WithumSmith+Brown, PC as auditor for the year ending December 31, 2026; approval of the amended and restated 2022 Equity Incentive Plan increasing the share reserve by 1,000,000 shares; and an amendment to the certificate of incorporation for a reverse stock split at a ratio between 1-for-5 and 1-for-20 chosen by the board. Why it matters: The reverse split is the proposal that matters, and its ratio is not fixed by this document: anywhere from 1-for-5 to 1-for-20, at the board's discretion, so a holder voting on it cannot know the resulting share count. Together with a 1,000,000-share increase to the equity plan reserve, both live proposals change the capital structure; the proxy states no other business.

●What changed:Definitive proxy statement (DEF 14A) soliciting shareholder votes for an amendment to extend the business combination deadline from September 16, 2026 to March 16, 2028, and for an adjournment proposal. BPGC Acquisition Corp. is seeking its sixth extension to avoid liquidation, proposing to amend its articles to push the deadline from September 16, 2026 to March 16, 2028. Public shareholders may redeem shares at approximately $12.18 per share (based on ~$1.3 million trust as of July 30, 2026). The sponsor, owning 98.7% voting power, ensures approval regardless of public vote. Why it matters: The filing sets the redemption deadline (September 14, 2026) and triggers a redemption opportunity at ~$12.18/share – above the typical $10.00 trust value. It reveals the SPAC has only ~$1.3 million remaining in trust (down from $345 million at IPO after massive redemptions). The extension gives more time to find a deal, but the sponsor’s near-total control means public shareholders have no meaningful vote on the extension. The document also details sponsor conflicts, delisting risks, and the possibility of PFIC tax treatment for U.S. holders.

●What changed:DEF 14A of SkinHealth Systems Inc. calling a virtual special meeting of stockholders for September 22, 2026 at 8:00 a.m. Pacific Time, with a record date of August 3, 2026 and proxy materials first made available on or about August 12, 2026. Proposal 1 asks stockholders to approve an amendment to the Restated Certificate of Incorporation combining outstanding Class A common stock into a lesser number of shares at a ratio of not less than 1-for-5 and not more than 1-for-20, with the exact ratio to be set within that range by the board in its sole discretion. Why it matters: The reverse split is proposed, not effected, and the ratio is a range the board would choose within — no specific ratio, effective date or resulting share count is stated in the notice.

●What changed:BiomX Inc. (NYSE American: PHGE) filed a definitive proxy statement for a special meeting on August 25, 2026 at 9:00 a.m. Eastern Time, held virtually, with a record date of August 10, 2026 on which 26,559,607 shares were outstanding; the quorum is one third of the voting power, or 8,853,203 votes. Why it matters: The issuance proposal is required because the Dr. Frucht consideration, the line of credit and the revenue bonus can together exceed the NYSE American thresholds — approving it authorises dilution whose size depends on facts not fixed at the vote. The split authority runs for a year and covers multiple splits totalling up to 1-for-20, and the authorized share count only falls if a split actually happens.

●What changed:CDT Equity Inc. (formerly Murphy Canyon Acquisition Corp.) filed a DEF 14A for its 2026 annual meeting on August 28, 2026, seeking approval of a reverse stock split (1-for-2 to 1-for-500), issuance of shares under a senior secured convertible note to J.J. Astor Co., and issuance of up to 12,131,770 shares upon exercise of pre-funded warrants. The filing also discloses the December 2025 sale of subsidiary Conduit Pharmaceuticals Limited to Corvus Capital (CEO Andrew Regan's firm) for $7,000,000 settled in stock and pre-funded warrants. Why it matters: The post-merger company has only 786,716 shares outstanding and is seeking authorization for aggressive reverse splits and large share issuances, signaling severe dilution and capital-structure risk. The sale of CPL to the CEO's own firm for $7M in equity raises significant related-party concerns and effectively transfers litigation liability to an insider entity.

●What changed:Definitive proxy statement (DEF 14A) soliciting shareholder votes at an extraordinary general meeting scheduled for August 20, 2026, to approve a six-month extension of TETE's business-combination deadline, an associated trust agreement amendment, and an adjournment proposal. TETE's board is asking shareholders to extend the combination deadline from August 20, 2026 to February 20, 2027; approve the corresponding trust agreement amendment; and allow adjournment if needed. The proxy discloses that the redemption price is approximately $13.36 per public share based on a trust account of approximately $144,602.65 as of August 7, 2026, versus a $12.08 closing price on the OTC Pink Market, with a redemption deadline of August 18, 2026. It also reiterates the target deal with Bradbury Capital Holdings Inc. and warns that without the extension TETE may be forced to liquidate. Why it matters: This filing sets the immediate redemption and voting calendar: public shareholders can redeem at approximately $13.36 per share by August 18, 2026, two business days before the August 20 meeting. If approved, TETE buys more time to close its Bradbury Capital Holdings deal until February 20, 2027; if not approved, TETE says it will wind down and liquidate the trust. The sponsor, with roughly 99.7% of outstanding shares, has said it intends to vote for the extension, making approval likely but not guaranteed.

●What changed:Definitive proxy statement (DEF 14A) for an extraordinary general meeting to approve amendments to the charter and trust agreement to extend the deadline to complete a business combination. Shareholders are asked to approve an extension of the deadline to complete a business combination from September 13, 2026 to up to September 13, 2027 via up to 12 monthly extensions, each funded by the sponsor at the lesser of $65,000 or $0.0333 per public share. The MicroTouch business combination was approved by shareholders on July 23, 2026, but its closing remains subject to Nasdaq listing approval; the board is uncertain whether it can close by September 13, 2026. Shareholders who do not vote for the extension may redeem at approximately $10.97 per share by August 19, 2026. Why it matters: Without the extension, the SPAC would be forced to liquidate if the MicroTouch deal does not close by September 13, 2026. The extension provides up to 12 additional months to close the deal or pursue an alternative. The filing details redemption rights, the coordination with prior redemptions from the business combination vote, sponsor incentives (founder shares worth ~$18.5M if deal closes vs $0 in liquidation, $830,900 in extension loans), and significant beneficial ownership information (sponsor 23%, Mizuho 8.9%, Karpus 6.48%). The outcome directly affects shareholder liquidity and the SPAC's survival.

What changed:Cardio Diagnostics Holdings, Inc. (the post-merger entity from Mana Capital Acquisition Corp.) filed a DEF 14A for its 2026 annual meeting on September 18, 2026, with a record date of July 31, 2026 and 2,959,469 shares outstanding. The proxy includes a proposal (No. 2) to approve the future issuance of shares equal to 20% or more of outstanding common stock in a non-public transaction to raise up to $10.0 million, consistent with similar proposals approved at the 2023, 2024, and 2025 annual meetings but never utilized. Why it matters: This filing confirms the post-merger company is operational and seeking continued shareholder authorization for potential dilutive capital raises, though it has relied on an ATM facility since early 2024. For SPAC trackers, it signals the de-SPAC entity is navigating ongoing capital needs and Nasdaq listing compliance rather than any new trust, extension, or redemption event.

●What changed:Definitive proxy statement (DEF 14A) for an extraordinary general meeting to approve changing the SPAC's name from Columbus Circle Capital Corp II to Inflection Point Acquisition Corp. VII, in connection with a new management team from Inflection Point Asset Management LLC, following the announcement of a business combination with Elroy Air. No change to trust value, redemption rights, or deadline. The SPAC is seeking shareholder approval to rename itself and adopt new articles of association reflecting the name change and new sponsor/management. The filing confirms that prior Chairman/CEO Gary Quin resigned and Michael Blitzer and Kevin Shannon (Inflection Point) were appointed. The Sponsor (Columbus Circle 2 Sponsor Corp) holds ~25.3% and will vote for. Adjournment proposal included if needed. Why it matters: This filing signals the SPAC is proceeding with its business combination with Elroy Air under new management from Inflection Point Asset Management, a serial SPAC sponsor (Inflection Point Acquisition Corp. VII). The name change is cosmetic but important for tracking sponsor conduct and deal progress. It also provides updated beneficial ownership, showing significant institutional holders (Adage, Linden, Tenor). No redemption event at this meeting, but the vote indicates the SPAC is on track to file a combined proxy/prospectus for the business combination later.

●What changed:Definitive Proxy Statement (DEF 14A). This document is a definitive proxy statement (DEF 14A) convened by the Board of Directors of Inception Growth Acquisition Limited for a Special Meeting of Stockholders on August 12, 2026. Per the Board's proposals, the business combination deadline will shift from August 13, 2026 to February 13, 2027 through concurrent amendments to the Certificate of Incorporation and the Investment Management Trust Agreement. The filing specifies that each one-month extension requires a deposit into the Trust Account calculated as $0.05 multiplied by the number of unredeemed Public Shares. According to management's consultation with Sponsor Soul Venture Partners LLC, the Sponsor will fund these deposits as interest-free loans repayable upon a business combination and forgiven upon liquidation except for non-trust funds. For redemption mechanics, the transfer agent requires written requests and physical or electronic share delivery by 5:00 p.m. Eastern Time on August 10, 2026. The Company states that as of July 29, 2026, the Trust Account held approximately $2,207,000, producing an estimated per-share redemption price of approximately $13.57, while the OTC Markets closing price that same date was $0.0011. On governance and personnel, the filing reports Soul Venture Partners LLC beneficially owns 1,195,990 shares (42.7%), controlled by Chairman and CEO Cheuk Hang Chow, a Hong Kong national.

●What changed:Tevogen Inc. — the successor to Semper Paratus Acquisition Corp, formerly Tevogen Bio Holdings — called its 2026 annual meeting for 24 August 2026, virtual, record date 23 July 2026. The proxy restates the deal history: the business combination under the 28 June 2023 merger agreement closed on 14 February 2024, and at closing the company paid SSVK Associates a $2.0 million Sponsor Advisory Services Fee for advisory services agreed in June 2023. The original sponsor converted all its Class B ordinary shares to Class A on 30 January 2023. Series B Preferred Stock is outstanding. Why it matters: The number that tells the story is the lock-up trigger: shares release only if the price holds $600.00 for 20 of 30 trading days. A threshold that size on a vehicle that IPO'd at $10 is the arithmetic of a large reverse split, i.e. the common has collapsed since the February 2024 close. Also on the record: a $2.0 million advisory fee paid to the sponsor's affiliate out of the closing, which is a direct transfer from the combined company to sponsor-side parties and belongs in Semper Paratus's sponsor track record.

What changed:GCT Semiconductor Holding, Inc., the successor to Concord Acquisition Corp III, called its 2026 annual meeting for September 17, 2026 at 4:00 p.m. Pacific Time by live audiocast with no physical location, record date July 24, 2026. Holders elect two Class II directors to serve until the 2029 annual meeting and ratify BPM LLP as auditor for the fiscal year ending December 31, 2026. Why it matters: Routine annual governance with no trust or redemption right surviving from the Concord III SPAC. The deferral mechanism means director RSUs accumulate off the current share count and settle later on a separation, change of control or death - so the dilution is real but deferred, and a change-of-control event would accelerate delivery of the whole deferred block at once.

●What changed:Definitive Proxy Statement (DEF 14A) for RF Acquisition Corp II's extraordinary general meeting scheduled for August 12, 2026, seeking shareholder approval for a charter amendment, trust agreement amendment, and adjournment proposal. Proposes to extend the deadline to consummate a business combination by up to six one-month extensions from August 15, 2026, to February 15, 2027, with $75,000 per month deposited into the trust account. Also proposes to eliminate the company's right to withdraw up to $100,000 of trust interest for dissolution expenses. The deal with Nanyang Biologics Pte. Ltd. remains pending, awaiting SEC effectiveness of Form F-4 and Nasdaq listing approval. The Business Combination Meeting is expected on or about August 19, 2026. Why it matters: Shareholders need to decide whether to redeem their public shares before the August 10, 2026, redemption deadline. The redemption price is approximately $11.07 per share, based on a trust account value of ~$53.5 million. The extension provides more time for the pending business combination to close but is not guaranteed. The removal of the dissolution expense withdrawal protects the trust value for public shareholders. The proposal needs a two-thirds vote for the charter amendment and 50% for the trust agreement amendment, with the sponsor holding 39.1% of shares.

●What changed:Andretti Acquisition Corp. II filed a definitive proxy statement (DEF 14A) for a shareholder meeting (extraordinary general meeting). Why it matters: Definitive proxy triggering a binding shareholder vote (typical extension/combination-related EGM). Material because a vote is scheduled; specific proposals not shown in the captured cover.

●What changed:A Definitive Proxy Statement (Form DEF 14A) soliciting shareholder votes at the Company’s Annual General Meeting on September 1, 2026. Per the filing, the Company proposes amending its Articles to extend the business combination deadline from September 9, 2026 to September 9, 2027 on a month-to-month basis. This extension is contingent on the Sponsor depositing the lesser of $30,000 or $0.03 per non-redeemed Public Share each month. The proxy statement discloses the Trust Account contained $9,114,765.64 as of July 14, 2026, projecting a pro rata redemption price of approximately $12.41 per Public Share as of July 29, 2026 after taxes owed but not paid, while noting a closing market price of $12.00 on July 28, 2026. According to the Board, the Company lacks sufficient time to consummate the proposed business combination agreement with Cartiga, LLC dated August 22, 2025 and hold a separate shareholder vote before the original deadline, necessitating this extension. The filing further reports that Nasdaq suspended trading on May 14, 2026 due to failure to comply with IM-5101-2 regarding the 36-month completion window from the May 4, 2023 IPO effectiveness date, moving the securities to the Pink Open Market under symbols ALCYF, ALCUF, and ALCWF. The Initial Shareholders, holding 3,413,000 ordinary shares acquired for $25,000 and private warrants purchased for $5,955,000, have waived rights to liquidating distributions and forfeited their interests if the combination fails or is not completed by the Extended Date. Why it matters: This filing materially resets the redemption calendar, establishing September 9, 2027 as the final liquidation horizon provided the Sponsor continues monthly funding. It presents public shareholders with a concrete mechanism to exercise redemption rights two business days prior to the September 1 General Meeting, highlighting a notable premium between the projected Trust payout (~$12.41) and the OTC trading price ($12.00). The Nasdaq delisting and subsequent OTC status, explicitly noted by the company, introduces structural liquidity and regulatory shifts that could impact future trading and target accessibility. The heavy concentration of voting power in the Sponsor and founders (approximately 75%) ensures approval is likely, but their substantial financial exposure ($25,000 in founder shares and $5,955,000 in private warrants at risk of total loss without a successful extension or combination) directly ties sponsor conduct to the urgency of closing the Cartiga transaction. Shareholders weighing immediate redemption versus continued merger exposure now have precise timing, cost, and liquidity parameters to evaluate.

What changed:BlackSky Technology Inc., the successor to Osprey Technology Acquisition Corp, called its annual meeting for 10 September 2026 at 1:00 p.m. Eastern, virtual, record date 16 July 2026. Business is ordinary-course for an operating public company: election of directors, ratification of the auditor, and an advisory say-on-pay vote on executive compensation. The letter is signed by Brian O'Toole, Chief Executive Officer, President and Director. The proxy describes 2025 activity of the nominating and corporate governance committee and its delegation rules under NYSE and SEC requirements. Why it matters: Nothing here concerns a trust or a redemption — and that is the finding. Osprey's vehicle is fully resolved into a listed operating company running a normal NYSE governance calendar, with no reverse split, no going-concern language and no capital-structure proposal in this notice. For a sponsor track record that is the good outcome, and it is the contrast case against the three reverse-split proxies filed by de-SPAC successors in the same fortnight.

●What changed:Immunovant, Inc., the successor to Health Sciences Acquisitions Corp, called its 2026 annual meeting for 2 September 2026, virtual, record date 8 July 2026. Three directors stand for election to the 2027 meeting: Jacob Bauer, Douglas Hughes and Robert Susman. The compensation tables value equity at the 31 March 2026 Nasdaq close of $24.84 per share. Why it matters: A routine annual meeting, but a useful marker: the successor to Health Sciences Acquisitions Corp is a functioning Nasdaq operating company whose stock closed at $24.84 on 31 March 2026, the outcome a sponsor track record should register. Note also a discrepancy in OUR record, not in the document: this CIK is stored with status LIQUIDATED while it is plainly filing as an operating Nasdaq company that completed its combination. A vehicle that completed a combination is not liquidated, and the status wants review.

●What changed:Definitive Proxy Statement (DEF 14A) for an extraordinary general meeting of Embrace Change Acquisition Corp. shareholders, filed with the SEC on July 21, 2026. Embrace Change is seeking shareholder approval to amend its charter and trust agreement to extend the deadline to complete a business combination from August 12, 2026, to August 12, 2027. The filing details the three proposals: (1) an amendment to the Articles of Association to extend the Combination Period; (2) an amendment to the Trust Agreement to effect the same extension; and (3) an adjournment proposal. Importantly, the filing also discloses that Embrace Change has repeatedly missed extension payments to the Trust Account, currently owing $40,000, and that these past violations could be the basis for shareholder lawsuits. Why it matters: This filing is material for investors tracking deadlines, sponsor conduct, and trust value. The SPAC is at risk of liquidation if the extension is not approved, as its current deadline is August 12, 2026. The trust has approximately $1.6 million with a per-share value of ~$12.84, significantly above the OTC trading price of $11.21. The Sponsor, holding ~91.7% voting power, intends to vote in favor. However, the disclosure of systematic late payments and a current $40,000 shortfall raises serious concerns about sponsor conduct and the viability of the proposed extension. The filing also notes an existing merger agreement with Tianji Tire Global, which is providing funding for extension payments.

●What changed:VSee Health, Inc., the successor to Digital Health Acquisition Corp, called its annual meeting for 25 August 2026 at 10:00 a.m. Eastern, record date 6 July 2026. Proposal No. 3 asks stockholders to grant the board discretionary authority to amend the certificate of incorporation to effect one or more consolidations of the outstanding $0.0001 par common stock — a reverse stock split, at the board's discretion, in one or more steps. Common trades on the Nasdaq Capital Market as VSEE and the redeemable public warrants as VSEEW. Why it matters: A board asking for open-ended, repeatable reverse-split authority is asking for the tool used to hold a Nasdaq listing when the bid price has fallen under $1.00. That is the standard post-de-SPAC distress sequence, and it belongs in Digital Health Acquisition Corp's outcome record. The warrants remain listed, so warrant holders face the same split arithmetic on an instrument that is already far out of the money.

●What changed:Definitive proxy statement (DEF 14A) convening a special shareholder meeting to vote on a nine-month charter extension and an adjournment proposal. This definitive proxy statement proposes amending the certificate of incorporation to extend the business combination deadline from August 18, 2026, to May 18, 2027. Per the Board’s recommendation, public stockholders may elect to redeem shares for approximately $12.84 before taxes or $12.63 after taxes (based on June 30, 2026 trust balances of $7.082 million before taxes and $6.967 million after taxes) by tendering certificates or using DWAC instructions by 5:00 p.m. Eastern Time on August 11, 2026. Management states the Board believes there is insufficient time to close the merger with Longevity Biomedical Inc. under the August 6, 2025 amended agreement before the current termination date, though management believes closing could occur before December 31, 2026. Approval requires at least 65% of the 4,061,674 outstanding shares as of the July 7, 2026 record date. The Sponsor controls 86.4% of votes, intends to vote for the amendment, will deposit up to $25,000 monthly (at $0.033 per unredeemed public share) for extensions, holds $3.45 million in extension loans, and the company issued zero-interest convertible notes of $100,000, $220,000, $200,000 and $200,000 between February and May 2026. The filing confirms the company’s position that redemptions are excluded from the 1% federal excise tax following Treasury regulations issued November 24, 2025.

●What changed:Definitive proxy statement (DEF 14A) filed by Inflection Point Acquisition Corp. V to solicit shareholder votes on an extension amendment proposal and an adjournment proposal at an extraordinary general meeting scheduled for August 12, 2026. The SPAC proposes to amend its articles to extend the deadline for completing an initial business combination from August 14, 2026 to August 31, 2026, with board authority to further extend up to four additional one-month increments to December 31, 2026. The filing sets the redemption deadline as August 10, 2026 (two business days before the meeting) and provides the anticipated redemption price of approximately $10.54 per share, based on the trust account balance as of June 30, 2026. It also discloses sponsor ownership (26.4% combined), vote thresholds, and potential insider non-redemption arrangements. Why it matters: This filing is critical for shareholders because it establishes the redemption deadline and meeting date, which determine whether shareholders can exit at the trust value of ~$10.54 before the extension. Without approval, the SPAC would liquidate by August 14, 2026. The extension is needed to complete the announced business combination with GOWell, but the filing also warns that even if approved, the deal may not close by the extended date. The disclosure of sponsor incentives and potential non-redemption agreements informs investors about conflicts of interest and the likelihood of approval.

●What changed:Definitive proxy statement (DEF 14A) for an extraordinary general meeting in lieu of annual meeting, seeking shareholder approval to extend the business combination deadline from August 5, 2026 to August 5, 2027, plus an adjournment proposal. Cartesian Growth Corporation II proposes a one-year extension of its deadline to complete an initial business combination. As of June 30, 2026, the trust account held approximately $38.4 million, implying an estimated redemption price of ~$12.47 per public share (vs. $12.00 market close on July 16, 2026). The meeting is set for July 27, 2026; redemption requests must be submitted by 5:00 p.m. ET on July 23, 2026. The sponsor (65.1% owner) will vote in favor, making passage virtually certain. Why it matters: Public shareholders face a redemption decision at ~$12.47 per share, above the current market price. If the extension is approved, the trust will be reduced by any redemptions, and the sponsor may purchase shares to limit redemptions (those shares cannot be voted for the extension). Without the extension, the SPAC would liquidate. The filing provides the first definitive trust value per share ($12.47) and the final redemption deadline.

●What changed:DEF 14A — definitive proxy statement, filed by SilverBox Corp IV, a Cayman Islands exempted company with a proposed business combination with Parataxis Holdings Inc., seeking shareholder approval to amend its articles to extend the deadline to complete a business combination and to remove the net tangible asset limitation on redemptions. The filing proposes: (1) an Extension Amendment to move the business-combination deadline from August 19, 2026 to December 19, 2026; (2) a Redemption Limitation Amendment to eliminate the $5,000,001 net-tangible-asset threshold that would otherwise limit redemptions; and (3) an Adjournment Proposal to permit further proxy solicitation if needed. The board states that it needs more time to complete the previously announced business combination with Parataxis Holdings Inc., and the Redemption Limitation Amendment is required to allow the SPAC to proceed with the Extension even if redemptions would push net tangible assets below $5,000,001. The meeting is set for August 11, 2026, with a redemption deadline of August 7, 2026. Shareholders who do not redeem now will retain their right to vote on and redeem in connection with the future business-combination vote. The trust account held ~$217.1M as of June 30, 2026 ($10.85 per share), and the public shares closed at $10.80 on July 16, 2026.

●What changed:Plum Acquisition Corp. III called an extraordinary general meeting for July 29, 2026 at 10:00 a.m. Eastern Time to extend its Termination Date from July 30, 2026 to December 31, 2026 by special resolution amending its Fourth Amended and Restated Memorandum and Articles. As of July 15, 2026 the trust held approximately $501,297, giving a redemption price of about $11.80 per public share. The Class A ordinary shares, no longer listed on a national securities exchange, last traded at $10.40 on May 1, 2026. Why it matters: The trust floor is $11.80 a share but the trust is down to roughly $501,000 - fewer than 43,000 public shares remain, so this is a shell with essentially no float. The market price of $10.40 sits $1.40 below trust, meaning redemption is worth materially more than selling. Holders who do not redeem carry deal risk to December 31, 2026 with no disclosed contribution accreting the trust in the meantime.

What changed:OSR Health, Inc. (Nasdaq: OSRH), the successor to Bellevue Life Sciences Acquisition Corp, called its annual meeting for 7 August 2026 at 10:00 a.m. Eastern, virtual only. The proxy states plainly why the meeting is being held: to comply with Nasdaq Listing Rule 5620(a), which requires an annual meeting for the election of directors within 12 months of the fiscal year ended 31 December 2025. The company describes itself as a life sciences holding company, and the agenda includes an amendment proposal. Why it matters: The company says in its own words that the meeting exists to satisfy a listing rule rather than to put a decision to shareholders, which is what a compliance-driven calendar looks like rather than a business one. For Bellevue's sponsor track record the useful fact is simply that the successor is still listed and current with Nasdaq's governance requirements as of August 2026.

●What changed:Definitive proxy statement (DEF 14A) for an annual meeting of stockholders to vote on a proposal to amend the charter to extend the deadline to complete a business combination from August 12, 2026 to August 12, 2027, and an adjournment proposal. The company is seeking stockholder approval to extend the business combination deadline. The board may elect to extend month by month to August 12, 2027, with each extension requiring a deposit of the lesser of $10,000 or $0.04 per public share into the trust account. The trust value as of June 30, 2026 was $5,718,028 (approximately $13.09 per public share). The redemption deadline for public stockholders is August 4, 2026 at 5:00 p.m. Eastern Time. The sponsor and insiders own approximately 78.3% of the outstanding common stock, making approval virtually certain. The document also details prior extensions and sponsor loans. Why it matters: This extension gives BYNO up to an additional 12 months to find a target. With only 436,743 public shares outstanding and sponsor control, the outcome is predetermined. Public stockholders have the right to redeem at approximately $13.09 per share, which exceeds the current market price of $12.65, creating a potential arbitrage opportunity. The company remains delisted from Nasdaq and trades on the OTC Pink Limited Market, heightening liquidity and risk. No business combination has been announced.

●What changed:Faraday Future Intelligent Electric Inc., the successor to Property Solutions Acquisition Corp., called a special meeting for August 12, 2026 at 9:00 a.m. Pacific Time, record date June 17, 2026, with materials mailed on or about July 15, 2026. Beneficial ownership is based on 346,155,245 shares of Class A Common Stock outstanding as of June 17, 2026, alongside 19,687,195 outstanding warrants. Each share of Series C Preferred Stock carries 3,846 votes and may vote on all proposals; conversion of the Series C into Class A remains subject to the limitations of Nasdaq Listing Rule 5635(d). Why it matters: A preferred share carrying 3,846 votes gives its holders voting power thousands of times that of a common share, so control of this meeting sits with whoever holds the Series C rather than with the 346.2 million Class A shares. The Nasdaq 5635(d) cap is the only brake on conversion, and votes of this kind are typically called to remove it. With 19.7 million warrants also outstanding, the dilution stack above the common is substantial.

●What changed:Nerdy Inc., the successor to TPG Pace Tech Opportunities, called a SPECIAL meeting for 13 August 2026 at 9:30 a.m. Eastern, virtual only, record date 9 July 2026, with 127,041,917 shares outstanding and entitled to vote. The notice states that no business other than the single proposal may be conducted: amendments to the certificate of incorporation to effect a reverse stock split of the Class A common stock. Why it matters: A special meeting called for one purpose, with the notice expressly barring any other business, is a board treating the split as urgent rather than routine — the usual driver being a Nasdaq or NYSE minimum-bid deficiency. On a 127.0 million share count that also fixes the arithmetic of the post-split float. For TPG Pace's track record this is the outcome line: the vehicle closed, and the successor is now consolidating its shares.

What changed:T3 Defense Inc. (successor to SPAC Brilliant Acquisition Corp) called its 2026 annual meeting for August 5, 2026 at 4:00 p.m. ET by webcast, with materials disseminated on or about July 10, 2026 and a record date of July 9, 2026, at which 126,311,902 shares of common stock were outstanding. Quorum is one-third of voting power. Director compensation ran $16,667 to $44,250 each. Ms. Kotaieva's term ended November 6, 2025 and Mr. Yeganeh resigned May 19, 2026. Mr. Shalom is entitled to a $175,000 relocation grant if he moves to the United States. Why it matters: Routine annual meeting mechanics rather than a trust or deal event, but the share count is the number to watch: 126,311,902 shares outstanding on the July 9, 2026 record date is more than double the 60,270,525 shares the company reported for its May 21, 2026 special meeting record date, evidence of rapid dilution from the warrant and preferred conversions then being approved. Executive equity awards that accrue quarterly when no plan capacity exists add further overhang, and the one-third quorum threshold means a small holder bloc can carry votes.

●What changed:A Definitive Proxy Statement (DEF 14A) soliciting shareholder approval to amend the company’s articles to extend the initial business combination deadline by twelve months and to authorize an adjournment mechanism if vote counts prove insufficient. The filing advances a proposal to extend the corporate existence and merger window from August 8, 2026 (the 'Current Termination Date') to August 8, 2027 (the 'Extended Date'). An Extraordinary General Meeting is set for August 4, 2026, with a July 1, 2026 record date for both voting and redemption elections. Public shareholders holding 14,375,000 Class A ordinary shares may elect to redeem those shares pro rata for trust account proceeds regardless of vote direction. Tenders must reach Continental Stock Transfer & Trust Company physically or via The Depository Trust Company’s DWAC system by 5:00 p.m., Eastern Time, on July 31, 2026. As of June 30, 2026, approximately $150.5 million sits in the trust account, which the proxy calculates as approximately $10.47 per share. The Nasdaq Global Market closing price on July 7, 2026, was $10.45. If the extension passes, New Sponsor (Collective Acquisition Sponsor LLC) will deposit into the trust account on August 8, 2026, and on the fifth day of each subsequent month until August 8, 2027, the lesser of (x) $35,000 or (y) $0.02 per public share multiplied by outstanding public shares. These deposits are documented as non-interest-bearing, unsecured promissory notes repayable only upon a completed business combination and forgivable upon liquidation. The company simultaneously agreed to cap the withdrawal of trust interest for dissolution expenses at up to $50,000, down from up to $100,000. Passing the amendment requires a two-thirds (2/3) special resolution of voted shares; establishing a quorum requires 10,116,407 ordinary shares present or represented. Why it matters: The arithmetic differential between the $10.47 redemption estimate and the $10.45 July 7, 2026 market price suggests a marginal cash-out advantage, though the proxy explicitly warns that open market liquidity may prevent shareholders from realizing that price at scale. The structured monthly contributions ($0.02/share capped at $35,000) are intended to replenish the trust account following redemptions, but the proxy discloses that management has neither asked New Sponsor to reserve for nor independently verified whether New Sponsor possesses sufficient capital to fund these obligations. Reducing the liquidation expense reserve from $100,000 to $50,000 preserves additional trust balance for public shareholders if the extension expires without a transaction. Because the five executive officers and directors collectively hold 5,750,000 founder shares representing approximately 28.4% of outstanding stock and have contractually waived all redemption and liquidation distribution rights on those securities, they stand to forfeit their entire initial capital outlay if no deal closes, heavily incentivizing approval of the extension or pursuit of a suboptimal target. Beyond mechanics, the board reports it is currently in serious discussions with a potential business combination target but declined to identify the industry, valuation, or negotiation stage. The proxy also documents a mid-year sponsor transition: Old Sponsor Dune Acquisition Holdings II LLC transferred 4,475,000 Class B shares and 1,000,000 private placement warrants to New Sponsor Collective Acquisition Sponsor LLC for $2,000,000, with the previous sponsor waiving a $2,000,000 repurchase right on May 4, 2026. Management confirmed a separate $15,000 monthly administrative utility fee payable to New Sponsor until business combination completion or liquidation, and engaged Sodali & Co. as proxy solicitor for approximately $10,000 plus reimbursed expenses. With no definitive agreement executed and no named counterparty, investors face a binary choice on July 31, 2026: accept the $10.47 pro rata trust distribution or retain exposure to an undisclosed pipeline under an extended, sponsor-funded timeline through August 2027.

What changed:Forum Markets, Incorporated (successor entity in the KBL Merger Corp. IV lineage) called its 2026 annual meeting for Wednesday, August 19, 2026 at 10:00 a.m., record date June 24, 2026, with 13,390,804 shares of common stock outstanding. Class II directors McAndrew Rudisill, Ryan Smith and Jason New stand for election; Class I directors Andrew Suckling, Crystal Heter, Angela Dalton and Michael Edwards serve until 2027. Reported 5% holders include Cyber Citadel at 2,080,389 shares (15.5%) and Electric Capital Partners Frontier Master Fund at 1,375,956 shares (10.3%). Why it matters: Governance-only filing with no trust, deadline or redemption consequence. The concentration disclosure is the substantive item for equity holders: two holders control roughly 26% of the 13.4 million shares outstanding, so board outcomes turn on a handful of votes. Outstanding option and warrant strikes disclosed at $29.20 and $30.10 per share, with expirations in 2035, sit far above a share base this small, indicating the equity has been heavily reverse-split and that those instruments are currently out of the money.

●What changed:Definitive Proxy Statement (DEF 14A) for an Extraordinary General Meeting to approve a charter amendment extending the SPAC's business combination deadline and a trust agreement amendment. LCCC proposes to extend its business combination deadline from August 1, 2026 to August 1, 2027 (up to 12 one-month extensions), each requiring a monthly deposit of up to $67,500 into the trust account. Shareholders may elect to redeem their public shares in connection with the vote; the redemption deadline is July 23, 2026. The trust account held approximately $72.1 million as of July 6, 2026, and the estimated per-share redemption price if fully extended is approximately $10.44. The filing also confirms the previously announced May 22, 2026 merger agreement with CPRO Electronics, which the board has unanimously approved and declared advisable. Why it matters: Approval is necessary to avoid forced liquidation on August 1, 2026. If approved, LCCC gains up to 12 additional months to close its pending business combination with CPRO. The filing sets key redemption mechanics and deadlines for public shareholders, and the expected significant redemptions may reduce trust assets. The proxy also discloses sponsor incentives and conflicts of interest, and lays out risks including CFIUS review and potential Investment Company Act implications.

●What changed:Definitive Proxy Statement (DEF 14A) for an annual meeting of stockholders to vote on proposals including extending the deadline to complete a business combination up to June 22, 2027, amending the trust agreement, electing directors, ratifying auditors, and adjourning the meeting. The SPAC is seeking stockholder approval to extend its deadline to complete a business combination from July 22, 2026 (after two prior monthly extensions) up to June 22, 2027, via up to 11 additional monthly extensions. Each extension requires a deposit of the lesser of $50,000 or $0.03 per outstanding public share. The trust agreement would be amended accordingly. Public stockholders have redemption rights at approximately $10.54 per share, with a deadline of July 17, 2026. The board recommends voting for all proposals. The sponsor, holding 26.8% of shares, intends to vote in favor. Why it matters: This filing is critical for investors monitoring the SPAC's timeline. Without approval, the SPAC would liquidate and redeem shares at ~$10.54. Approval gives the SPAC nearly a year more to find a deal, but redemptions could reduce trust cash and may cause Nasdaq delisting if public float falls below requirements. The redemption price (~$10.54) is slightly above the current market price ($10.44), providing a small arbitrage for those who redeem. The sponsor's large stake and waiver of redemption rights indicate strong insider support, but the outcome depends on public stockholder votes. The filing also discloses that the SPAC is in discussions with a potential target, suggesting a deal may be imminent.

●What changed:DEF 14A definitive proxy statement soliciting stockholder approval to extend the deadline to complete a business combination from July 18, 2026 to April 18, 2027 (up to nine one-month extensions) and to adjourn the special meeting if necessary. The SPAC proposes amending its charter to extend the termination date by up to nine months (to April 18, 2027), removing the requirement for monthly deposits into the trust account. Public stockholders may redeem shares at ~$11.01 per share (trust balance ~$414,070 as of June 29, 2026). The special meeting is set for July 17, 2026, with redemption deadline July 15, 2026. Why it matters: If the extension is not approved, the SPAC will liquidate and public stockholders receive ~$11.01 per share. Approval gives more time to close the pending merger with Aiways Automobile Europe GmbH (BCA signed Nov 2024, Form F-4 filed Feb 2026). However, the SPAC is already delisted from Nasdaq (Jan 2025), trust is very small, and sponsor (98.27% owner) intends to vote for, making approval likely but the path to a completed deal remains uncertain.

●What changed:Zeo Energy Corp. (successor to SPAC ESGEN Acquisition Corp) called its annual meeting for August 7, 2026 at 3:00 p.m. ET at virtualshareholdermeeting.com/ZEO2026, record date June 30, 2026. Alongside electing directors including Timothy Bridgewater, Abigail M. Allen, James P. Benson and Neil Bush and ratifying Tanner LLC as auditor, Proposal 2 asks holders to approve under Nasdaq Listing Rule 5635(d) the future issuance of Class A common stock at or above 20% of shares outstanding as of June 9, 2026 on conversion of promissory notes issued to White Lion Capital LLC. Why it matters: The Nasdaq 20% proposal is a request for pre-approval of open-ended convertible note dilution: once granted, White Lion can convert notes into Class A shares beyond the 20% cap that would otherwise require a separate vote. Convertible facilities of this type typically price off a discount to market, so issuance grows as the share price falls, which is the classic death-spiral structure for post-SPAC issuers. Legacy ESGEN holders who stayed in through the deal bear that dilution, and the company's need for the facility signals a constrained cash position.

●What changed:Definitive Proxy Statement (DEF 14A) for an Extraordinary General Meeting of Shareholders to vote on proposals to amend the investment management trust agreement and the charter, extending the SPAC's business combination period and trust liquidation timeline. Keen Vision Acquisition Corporation’s Board proposes extending the deadline to consummate a business combination from July 27, 2026 to July 27, 2027. To effect this, the Board seeks shareholder approval to amend the Trust Agreement, allowing up to four additional three-month liquidation extensions funded by a $30,000 deposit per extension for all remaining public shares. The Board also proposes a Charter Amendment to formally update the termination date to July 27, 2027. Public shareholders who do not approve these changes will face liquidation after July 27, 2026. For those who do approve, the filing outlines a redemption election process requiring public holders to tender shares to Continental Stock Transfer & Trust Company at least two business days prior to the July 21, 2026 meeting to receive a pro rata portion of the Trust Account. The Board recommends voting “FOR” all proposals. Why it matters: This filing governs the immediate redemption deadline and mechanical pathways for liquidity ahead of the July 21, 2026 vote. As of June 29, 2026, the Company reports approximately $13,428,491.47 in the Trust Account, representing a per share pro rata amount of approximately $12.314, while the closing price for KVAC’s shares on that same date was $12.16. The extension relies on KVC Sponsor LLC funding non-interest-bearing monthly extension loans into the Trust Account. Sponsor conduct is detailed through waivers of liquidating distributions on the sponsor’s founder and private placement shares if the combination fails before July 27, 2026, and an indemnification commitment to maintain trust proceeds at no less than $10.15 per public share against specific third-party claims. The proxy discloses material strategic constraints: because the sponsor is controlled by Canadian citizen Kenneth Wong, potential U.S. targets in federally licensed industries may face foreign ownership restrictions or require CFIUS review, potentially limiting acquisition opportunities or delaying approvals. The filing also warns that operating past the Company’s 36-month IPO anniversary in July 2026 exposes the securities to Nasdaq delisting. On the record date of June 24, 2026, insiders hold approximately 77.7% of outstanding shares and intend to vote in favor of the extensions.

●What changed:QT Imaging Holdings, Inc., the successor to GigCapital5 (GIA), called its 2026 annual meeting for July 28, 2026 at 1:00 p.m. Eastern Time, held virtually, record date June 23, 2026. Proposal 3 would increase the shares reserved under the equity plan from 1,827,278 by 550,900 shares - 4% of shares outstanding - to 2,378,178. Net loss for 2025 was $21.1 million, or $2.01 per share, including other expense of $8.8 million of which $6.6 million was non-cash expense at issuance of the Lynrock Lake Term Loan. Why it matters: A $21.1 million net loss against a share count small enough that $2.01 per share of loss is the result means the company is burning far more than its equity base can absorb without further raises - and $6.6 million of that loss was the non-cash cost of taking on the Lynrock Lake term loan, so debt has already been used. The October 2025 reverse split and January 2026 Nasdaq uplisting restored the listing, but the plan increase adds 4% dilution on top.

What changed:Owlet, Inc. (successor to SPAC Sandbridge Acquisition Corp) called its 2026 annual meeting for Wednesday, August 12, 2026 at 1:00 p.m. ET, entirely virtual, using notice-and-access delivery to holders of record at the close of business on June 15, 2026. As of that record date there were 29,063,954 shares of common stock outstanding, 11,479 shares of Series A Preferred representing 1,673,320 shares of voting power, and 9,250 shares of Series B Preferred. Pay-versus-performance tables show 2025 net loss of $39.678 million and a $100 initial investment worth $206.87. Why it matters: Routine annual governance with no SPAC trust exposure remaining. The capital structure detail is what matters to common holders: 11,479 Series A preferred shares carry 1,673,320 votes, roughly 5.4% of the 29.1 million common shares outstanding, and a Series B layer sits behind it, so preferred holders vote together with common and rank ahead of them in liquidation. Owlet remained loss-making in 2025 at $39.7 million while total shareholder return more than doubled to $206.87 per $100, meaning the valuation rests on expectations rather than earnings.

●What changed:Cycurion, Inc., the successor to Western Acquisition Ventures Corp., called its 2026 annual meeting for 12:00 p.m. Eastern Time on July 23, 2026 in person at its principal executive office at 1640 Boro Place, Suite 420C, McLean, Virginia, record date June 1, 2026, with eight proposals. At the record date there were 10,662,429 shares of common stock and 6,786,417 shares of preferred stock outstanding. Series A Convertible Preferred converts at 25.6938 common shares per preferred share subject to 4.99% or 9.99% blockers. Why it matters: The preferred stack dwarfs the common: 6,786,417 preferred shares converting at 25.7 common each would produce far more shares than the 10,662,429 common outstanding, so existing holders face dilution of an order of magnitude, restrained only by ownership blockers that slow rather than prevent conversion. A CFO change taking effect the day the record date was set adds reporting risk. The Western Acquisition trust was released at the de-SPAC.

●What changed:This filing is a Definitive Proxy Statement (Form DEF 14A) and Notice of Extraordinary General Meeting filed by M3-Brigade Acquisition V Corp. to solicit shareholder votes on six proposals regarding corporate charter amendments, trust account adjustments, name change, fairness opinion removal, and meeting procedure ahead of the July 17, 2026 gathering. The proxy statement discloses that the Board executed a Mutual Termination Agreement on June 12, 2026 to end the ReserveOne Business Combination citing changed market dynamics and investor feedback. To avoid mandatory liquidation under the existing August 2, 2026 deadline, the Board proposes a special resolution to extend the consummation period by 12 months to August 2, 2027. Public shareholders may exercise redemption rights by submitting written requests to the transfer agent no later than 5:00 P.M. Eastern Time on July 15, 2026. The filing authorizes the Company to withdraw up to $0.10 per outstanding Class A Ordinary Share held by non-redeeming public shareholders from trust interest, allocating $1,000,000 to ordinary course expenses and any excess to accrued liabilities. Concurrently, the Sponsor and third parties entered agreements on June 12, 2026 securing approximately 16,000,000 Class A Ordinary Shares against redemption in exchange for up to 8 million transferred private placement warrants. The Sponsor also signed Securities Purchase Agreements to sell 4,279,279 converted Class B Ordinary Shares at $3.33 per share, generating $14,250,000 in gross proceeds that the Sponsor intends to use to make loans up to $4,000,000 to the Company for covered expenses. The proxy states the Trust Account held approximately $312,197,620 as of June 26, 2026, estimating a redemption price of $10.86 per share. The Company’s legal name will change to Velos Acquisition I Corp., and the sponsor definition will update to MI7 Sponsor, LLC. Why it matters: The Board asserts that moving the liquidation deadline to August 2, 2027 provides necessary time to identify a new business combination after the ReserveOne termination, while the July 15, 2026 redemption window allows exiting shareholders to receive cash based on the then-current trust valuation. The $0.10 per-share interest withdrawal permanently directs accrued trust earnings toward operational liabilities and expenses rather than preserving them for future redemptions or liquidation distributions. The Sponsor-backed $14,250,000 equity transaction and associated $4,000,000 loan facility inject working capital to sustain deal-search activities without public dilution. Binding non-redemption commitments covering roughly 16,000,000 shares, combined with the Sponsor and aligned voting parties controlling approximately 74% of voting power as reported in the statement, indicate the proposals will likely pass without broad public support. The Board states that removing the fairness opinion requirement for affiliated transactions reduces transaction costs and offers flexibility for volatile target industries, though it eliminates an independent valuation safeguard for minority holders. The filing notes the Company has generated no revenue to date, maintains executive offices at 200 Park Avenue, New York, NY, and plans to pivot its strategy away from its original digital asset treasury objective toward an undefined new target following the corporate renaming.

What changed:Reservoir Media, Inc. (successor to SPAC Roth CH Acquisition II Co) called its 2026 annual meeting for August 6, 2026 at 12:00 p.m. ET as a virtual meeting, with the proxy dated June 26, 2026 and signed by chief executive Golnar Khosrowshahi. Pay-versus-performance disclosure shows fiscal 2026 net income of $7,826,515, PEO summary compensation of $1,594,984 against $1,881,343 actually paid, and a $100 initial investment worth $123.46. The common stock closed at $7.63 on March 31, 2025 and $9.79 on March 31, 2026. Why it matters: Routine annual governance with no residual SPAC trust, deadline or redemption mechanics. Reservoir is one of the rarer de-SPACs disclosing positive GAAP net income, $7.8 million in fiscal 2026, and the share price rose from $7.63 to $9.79 over the fiscal year, a 28% gain that lifted the $100 initial investment measure to $123.46. Executive compensation actually paid of $1.9 million against $7.8 million of net income is proportionate rather than the outsized equity grants common in the post-SPAC cohort.

●What changed:Zoomcar Holdings, Inc. (successor to SPAC Innovative International Acquisition Corp) called a virtual annual meeting for July 20, 2026 at 11:00 a.m. ET, record date June 26, 2026. The agenda includes a tender offer proposal, an inducement grant for chairman Uri Levine (appointed effective March 31, 2025), a reverse stock split proposal and an adjournment proposal. Capitalization is 250,000,000 authorized common shares with about 8,488,485 outstanding as of June 26, 2026 and 1,630 preferred outstanding, against a fully diluted figure of up to 509,192,089 shares. Why it matters: The gap between roughly 8.5 million shares outstanding and up to 509.2 million shares on a fully diluted basis is the entire story: existing common holders face potential dilution of about sixty times if the convertible and warrant instruments are exercised in full, which also exceeds the 250 million authorized share ceiling and explains the reverse split on the same ballot. A reverse split creates the authorized headroom for those conversions rather than fixing the underlying dilution, so legacy SPAC holders should treat the split as enabling, not remedial.

●What changed:Getaround, Inc. (successor to SPAC InterPrivate II Acquisition Corp) called a special meeting for Wednesday, July 29, 2026 at 11:00 a.m. ET by webcast, record date June 17, 2026, to vote on a dissolution proposal plus an adjournment proposal. The proxy warns that failure to complete the process on schedule, or prior to October 31, 2026 if the SEC reviews the proxy and issues comments, would default the Funding Agreement, letting the lender terminate it, after which no further funding would come under the New SPN and the company may lack money for an orderly wind-down. Why it matters: This is a wind-down vote, the terminal outcome for a de-SPAC: holders are being asked to approve dissolution rather than any strategic alternative. The October 31, 2026 date is a hard financing cliff, because the lender can walk from the Funding Agreement if SEC review delays the vote, and the company states it may then be unable to fund even an orderly liquidation, which would push the process toward bankruptcy where common holders recover nothing. Mudrick Capital, holder of a $3.0 million promissory note issued August 7, 2023, ranks ahead of equity.

What changed:Spruce Power Holding Corporation (successor to SPAC Pivotal Investment Corp II) called its 2026 annual meeting for August 11, 2026 at 11:00 a.m. ET solely by live audio webcast, with proxy materials first made available on or about June 25, 2026 and a record date of June 16, 2026. Business is the election of Class C directors by plurality vote and ratification of the independent registered public accounting firm for the year ending December 31, 2026. The company notes NYSE listing standards requiring a majority-independent board and fully independent audit and compensation committees. Why it matters: Ordinary-course annual governance with no trust, extension or redemption consequence for legacy SPAC holders. Plurality voting for the Class C slate means nominees are elected on the votes cast regardless of withheld votes, so the election carries no practical contest risk. Brokers retain discretionary authority to vote uninstructed shares on the auditor ratification but not on director elections, which is the usual pattern and lowers effective turnout on the board vote.

●What changed:Vicarious Surgical Inc. (successor to SPAC D8 Holdings) called a special meeting for Monday, July 21, 2026 at 9:00 a.m. ET, in person at 78 Fourth Avenue, Waltham, Massachusetts, record date June 10, 2026, to approve an assignment for the benefit of creditors followed by voluntary dissolution and liquidation under a plan attached as Annex A. Based on cash, money market funds, U.S. treasury and agency securities as of March 31, 2026, the company does not expect to continue as a going concern for any significant period. 6,477,365 Class A and 653,990 Class B shares are outstanding. Why it matters: An assignment for the benefit of creditors places company assets under an assignee who pays creditors first, so common stockholders receive residual value only if creditors are made whole, and the company's own going-concern language says cash is insufficient to continue for any significant period. Management adds that strategic alternatives and financing are unlikely to succeed. For anyone holding the former SPAC's shares this is effectively a zero: the trust redemption right was extinguished at the business combination and there is no floor beneath the equity now.

●What changed:Greenland Mines Ltd, formerly Klotho Neurosciences and successor to SPAC Redwoods Acquisition Corp, called a virtual-only special meeting for July 16, 2026 at 1:00 p.m. ET via Zoom, record date May 18, 2026, with 121,238,660 shares of common stock outstanding. Proposal 1 seeks approval under Nasdaq Listing Rule 5635 for the issuance of up to 2,040,038,760 shares of $0.0001 par common stock in connection with the March 4, 2026 acquisition of Greenland Mines Corp. under an Agreement and Plan of Merger entered that date. Quorum is one-third of outstanding capital stock. Why it matters: Approving up to 2,040,038,760 new shares against 121,238,660 outstanding would expand the share count roughly seventeenfold, cutting existing holders to under 6% of the company. That is the price of the Greenland Mines acquisition, and the Nasdaq 5635 vote exists precisely because issuances of this scale transfer control. Legacy Redwoods SPAC holders who did not redeem hold the diluted side of that trade. The one-third quorum threshold means the authorization can pass on a thin vote.

●What changed:System1, Inc. (successor to SPAC Trebia Acquisition Corp) called its annual meeting for Wednesday, July 22, 2026 at 11:00 a.m. Pacific Time at virtualshareholdermeeting.com/SST2026, record date June 18, 2026, with Class A and Class C common stock voting. Proposal 1 asks holders to approve, for purposes of the NYSE listing rules, the issuance of Preferred Shares. The preferred matures on January 14, 2031, when the company must redeem all outstanding Preferred Shares for cash at the then-applicable liquidation value, subject to conversion rights. Three Class I directors also stand for election. Why it matters: The preferred issuance is a senior claim ahead of common: distributions to common stock and other junior equity are blocked until the preferred is served, and the January 14, 2031 mandatory cash redemption at liquidation value creates a fixed future cash obligation the company must fund or refinance. Holders' conversion rights mean the alternative outcome is share issuance and dilution to common. The NYSE vote is required because the issuance is large enough to shift control or exceed the 20% threshold, so either path costs existing equity.

●What changed:Oak Woods Acquisition Corporation set an extraordinary general meeting for July 8, 2026 at 12:00 p.m. ET, record date June 16, 2026, to amend its charter and extend the business combination deadline past the March 28, 2026 outside date, which it passed without effectuating the liquidating redemption or starting Cayman liquidation. Prior extensions required monthly trust deposits of $42,998.37. At the record date trust held about $16,446,537.85, roughly $12.62 per share. Shares were delisted from Nasdaq on March 23, 2026 and trade over the counter. Why it matters: The trust floor is intact at roughly $12.62 per share and continues to accrue, so redeeming holders are still paid out well above the $10.00 IPO price, but the SPAC is operating past its own outside date without having redeemed, which is a governance failure that leaves shareholders relying on the board rather than the charter. The March 23, 2026 Nasdaq delisting removes exchange liquidity and forces OTC trading, typically at a discount to trust, and it also disqualifies the vehicle from many deal structures, narrowing the chance of any combination completing before liquidation.

●What changed:Definitive proxy statement (DEF 14A) filed by Plum Acquisition Corp. IV for an extraordinary general meeting of shareholders to be held on July 2, 2026, to vote on an extension amendment proposal and an adjournment proposal. Plum is seeking shareholder approval to amend its articles of association to extend the deadline to consummate a business combination from July 16, 2026 (Original Termination Date) to January 16, 2027, with the ability to further extend monthly up to six times (to July 16, 2027) without additional shareholder vote, upon sponsor request and board resolution. The extension is needed because the previously announced business combination with Controlled Thermal Resources Holdings Inc. (CTR) will not close by the original deadline. An adjournment proposal is also included to allow additional solicitation if needed or to address Nasdaq listing requirements. Why it matters: This vote determines whether the SPAC will continue to pursue the CTR deal or liquidate. If the extension is not approved and no business combination closes by July 16, 2026, Plum will liquidate, redeeming public shares at approximately $10.67 per share (as of June 12, 2026) and warrants will expire worthless. The trust account holds about $184,121,199. The sponsor (Plum Partners IV, LLC) owns 27.9% of shares and will vote for the extension; they have invested $4,425,000 and would lose their entire investment in liquidation. Shareholders may redeem their shares in connection with the extension at a per-share price based on trust value. The filing provides redemption deadlines (June 30, 2026), voting requirements (two-thirds majority for extension), and details on sponsor conflicts of interest.

What changed:Jasper Therapeutics, Inc. (successor to SPAC Amplitude Healthcare Acquisition Corp) called its 2026 annual meeting for Friday, July 31, 2026 at 10:00 a.m. Pacific Time by live webcast, record date June 5, 2026. The proxy discloses 2025 general and administrative expenses of $20.8 million including $4.7 million of stock-based compensation and a net loss of $75.8 million, or $3.95 per basic and diluted share. Effective January 5, 2026 Mr. Wiggans became Executive Chairperson concurrently with the appointment of Mr. Mahal as Chief Executive Officer and President. Why it matters: Routine annual governance, but the financials define the risk: a $75.8 million net loss in 2025 against a share count implied by the $3.95 loss per share of roughly 19 million shares means the company burns far more each year than a small-cap equity base can absorb without repeated dilutive financings. A simultaneous CEO change and elevation of the chairman to an executive role in January 2026 signals a strategic reset. Legacy Amplitude SPAC holders have no trust claim; their downside is the full equity risk of a clinical-stage biotech.

●What changed:Four Leaf Acquisition Corporation filed a definitive proxy dated June 12, 2026 for a June 22, 2026 virtual special meeting with four proposals: (1) charter amendment allowing the board to extend the combination deadline up to 12 additional one-month increments from June 22, 2026 to June 22, 2027; (2) amendment to the March 16, 2023 trust agreement with Continental requiring a $75,000 deposit per one-month extension, funded by the Sponsor against non-interest-bearing extension notes repayable only on closing; (3) elimination of the $5,000,001 net-tangible-assets redemption limitation so shares can be redeemed without that floor; and (4) adjournment. Approval of both extension proposals is a condition to the extension, and without it the company may be forced to liquidate. Why it matters: Extends Four Leaf's life by up to a year at $75,000 per month while removing the $5,000,001 NTA floor — a signal that management expects redemptions large enough to breach it, and that the sponsor's extension notes will go unpaid if no deal closes.

●What changed:Definitive proxy statement (DEF 14A) soliciting shareholder votes to amend the charter to extend the deadline for an initial business combination, to appoint an auditor, and to adjourn the meeting if necessary. The company proposes to extend the deadline to complete a business combination from July 3, 2026 to July 3, 2027 (with up to 12 monthly extensions). It also seeks shareholder approval to engage Marcum Asia CPAs LLP as auditor for FY2026. The trust account held approximately $33.46 million as of the June 5, 2026 record date, with an estimated redemption price of $11.42 per share. The company disclosed it received a Nasdaq deficiency notice for failing to maintain 300 public holders (cure extension granted through October 3, 2026) and that the sponsor and target have funded extension fees via promissory notes. Why it matters: The charter amendment is essential to avoid liquidation. If approved, the SPAC gains another year to close its announced business combination with Marine Thinking (autonomous ship and fleet solutions). If not approved, the company will redeem public shares and dissolve after July 3, 2026. The redemption rights give shareholders an exit at ~$11.42, while the stock traded at $12.89 on the record date, so selling in the open market would yield more. The filing also reveals sponsor and target funding of extension costs and Nasdaq listing challenges, providing key context on sponsor commitment and regulatory risk.

What changed:PSQ Holdings, Inc. (successor to SPAC Colombier Acquisition Corp, whose deal closed July 19, 2023) called its annual meeting for Thursday, July 9, 2026 at 11:00 a.m. ET online at virtualshareholdermeeting.com/PSQH2026, record date June 8, 2026, at which 49,946,333 shares of Class A common stock were outstanding. Effective February 27, 2026 all outstanding Class C common stock converted. Holders elect three Class III directors serving until 2029, ratify UHY LLP as auditor for the year ending December 31, 2026, and vote on a charter amendment. Why it matters: Ordinary post-deal governance with no trust or redemption mechanics remaining for legacy Colombier holders. The structural change worth noting is the February 27, 2026 conversion of all Class C shares, which folds a separate class into the common base and increases the Class A count against which future issuances are measured. Management turnover continued, with Mr. Herbert moving from Chief Operating Officer to Senior Vice President of People effective January 6, 2026 and resigning outright on May 31, 2026.

●What changed:Definitive Proxy Statement convened by Launch One Acquisition Corp. to solicit shareholder votes at an Extraordinary General Meeting in lieu of an Annual General Meeting. The filing proposes amending the Company’s Articles to extend the deadline to consummate an initial business combination from July 15, 2026, to January 15, 2027. It activates a shareholder redemption election exercisable prior to 5:00 p.m. Eastern Time on July 2, 2026, priced at approximately $10.83 per share based on a reported Trust Account balance of approximately $249,132,955 as of June 2, 2026. The document confirms a Working Capital Promissory Note executed on March 20, 2026, authorizing the Sponsor to lend up to $1,000,000 across three tranches, secured by a pledge of 2,932,500 founder shares to Keystone Capital Partners, LLC. The Sponsor states it intends to vote all 5,750,000 founder shares in favor of the extension and related proposals. Why it matters: According to the proxy statement, the Board concludes that there may not be sufficient time before July 15, 2026, to conduct a separate shareholder vote for a Potential Business Combination and consummate a closing without this extension. Shareholders face a direct liquidity decision: tender shares for redemption at the calculated pro rata trust value before the July 2, 2026 deadline, or retain exposure to a search period where the company discloses having no definitive agreement with a target entity. The filing warns that large-scale redemptions could deplete trust cash below thresholds required for business combination closing conditions or trigger Nasdaq delisting proceedings, as the exchange generally requires a minimum of 400 public holders. Management also discloses that 6,000,000 private placement warrants were previously issued to Sponsor and Cantor Fitzgerald & Co. at $1.00 each, totaling $6,000,000 in gross IPO-side proceeds, with an exercise price of $11.50 per share that remains unexercised until after a business combination. The working capital facility carries an 8% annual interest rate, a 20% original issue discount, and defaults interest at an additional 18%, with repayment dependent on successful deal execution. Furthermore, the filing notes audit fees of $116,895 for the year ended December 31, 2025 and $128,440 for the inception period through December 31, 2024, paid to WithumSmith+Brown, PC, whose appointment the Board recommends ratifying. The Board attributes all extension recommendations to fiduciary assessments that continuing the search period serves shareholder interests by preserving optionality for a Potential Business Combination valuation event.

●What changed:BiomX Inc., the successor to Chardan Healthcare Acquisition Corp., called its 2026 annual meeting for June 26, 2026 at 9 a.m. Eastern Time in a virtual-only format, record date June 2, 2026. Michael Oster, age 54, was appointed Chief Executive Officer effective March 4, 2026, having previously led mergers and acquisitions at Alon USA Energy. The proxy discloses that on April 10, 2026 the company entered into and simultaneously closed a Stock Purchase Agreement with Water IO Ltd., acquiring all of the issued and outstanding share capital of that company. Why it matters: A new chief executive with an M&A and energy background rather than a clinical one, followed a month later by the immediate closing of an acquisition of Water IO, signals a strategic redirection away from the phage therapy business the Chardan SPAC financed. Simultaneous signing and closing means the transaction was completed without a shareholder vote, so holders learn of the pivot after the fact rather than approving it.

●What changed:Definitive proxy statement (DEF 14A) for an extraordinary general meeting to approve an amendment to extend the deadline for completing an initial business combination. The company proposes to extend the outside date from June 27, 2026 to September 27, 2026, with potential further extensions up to December 27, 2026 if a definitive agreement is signed. The board states there is insufficient time to complete a deal before the current deadline. Shareholders have redemption rights at approximately $10.83 per share, with a redemption deadline of June 24, 2026. Why it matters: This filing triggers a redemption opportunity for shareholders at the trust value. The extension is critical to avoid immediate liquidation. The filing also discloses sponsor interests and potential insider purchases, which may influence shareholder decisions. The meeting is on June 26, 2026, and the redemption deadline is June 24, 2026, so investors must act quickly.

●What changed:Arogo Capital Acquisition Corp. called a special meeting in lieu of its 2026 annual meeting for June 26, 2026 at 9:00 a.m. ET to vote on an extension amendment. The deadline to complete a business combination is June 29, 2026 and sponsor Singto, LLC, formerly Koo Dom Investment, LLC, has indicated it does not intend to fund the deposit the certificate requires to extend. It anticipates a per-share redemption price of about $11.53 from trust at the meeting. Without approval it must cease operations and redeem public shares within 10 business days. Shares trade on the OTC Pink Sheets. Why it matters: The trust floor is approximately $11.53 per public share and is payable within ten business days if the extension fails, so the downside for a holder buying below that level is bounded and near-term. The critical disclosure is that the sponsor will not fund the extension deposit, removing the usual cushion and making liquidation the base case unless shareholders approve an extension the sponsor is not paying for. Any deal completed after such a vote would be attempted by a sponsor unwilling to commit fresh capital, and OTC trading already signals lost exchange listing.

●What changed:Borealis Foods Inc. (successor to SPAC Oxus Acquisition Corp) called its annual meeting for Monday, June 29, 2026 at 12:30 p.m. ET at virtualshareholdermeeting.com/BRLS2026, record date May 26, 2026, to present financial statements and ratify the auditor for the year ending December 31, 2026. Auditor BPB's reports for the years ended December 31, 2024 and 2023 each carried an emphasis of matter on substantial doubt about the company's ability to continue as a going concern. Director Shiv Vikram Khemka resigned from the board and all three committees on May 11, 2026. Why it matters: Two consecutive years of going-concern qualifications, on the 2023 and 2024 audits, is the substantive disclosure: the auditor has twice signalled doubt that the company can fund operations, which usually precedes dilutive equity raises, asset sales or restructuring. The change of auditor alongside those opinions, and a director resigning from the board and every committee on May 11, 2026, compound the governance concern. Legacy Oxus SPAC holders who did not redeem carry ordinary equity risk with no trust protection behind it.

●What changed:Triller Group Inc. (successor to SPAC AGBA Acquisition Ltd) called its 2025 annual meeting for June 10, 2026 at 1:00 p.m. local time at 20F Foyer, 625 King's Road, North Point, Hong Kong, record date May 13, 2026. Beyond electing directors and ratifying Enrome LLP as auditor for the year ending December 31, 2025, holders vote on a name change, on a 2026 Equity Incentive Plan reserving 39,600,000 shares, and on a Nasdaq Rule 5635(d) proposal permitting issuance of stock or convertible securities in one or more private placements above 20% of outstanding common. Why it matters: Two dilution authorizations sit on the same ballot: a 39.6 million share incentive pool and open-ended private placement capacity above the Nasdaq 20% threshold, meaning management is seeking pre-clearance to issue equity repeatedly without returning to shareholders. For legacy AGBA holders that is compounding dilution on top of a de-SPAC that is already holding its fiscal 2025 annual meeting in mid-2026, a delay indicating reporting strain. An in-person Hong Kong venue with no virtual option also suppresses participation by U.S. retail holders.

What changed:PLAYSTUDIOS, Inc., the successor to Acies Acquisition Corp., called its annual meeting for Friday, July 10, 2026 at 8:00 a.m. Pacific Time by live webcast, record date May 18, 2026, to elect five directors for one-year terms and ratify Deloitte & Touche LLP for the fiscal year ending December 31, 2026. Why it matters: The Sponsor forfeiting 1,657,188 shares cut founder dilution by roughly 31% of the original block, a genuine benefit to public holders that many de-SPACs never delivered. The offsetting item is that the private placement warrants cannot be redeemed by the company while the Sponsor or its transferees hold them, so that dilution sits outstanding indefinitely. Annual one-year director terms give holders full board accountability each year.

●What changed:This document is a DEF 14A Definitive Proxy Statement for an Extraordinary General Meeting of Shareholders, drafted by the Registrant's Board of Directors and signed by Chief Executive Officer Qi Gong on May 29, 2026. Per Qi Gong's May 29, 2026 filing, the Board proposes amending the Company’s Second Amended and Restated Memorandum of Association and Investment Management Trust Agreement to move the termination date from June 19, 2026 to October 19, 2026, allowing month-to-month extensions for up to four one-month periods. The Board states that for each extension, the Sponsor will deposit $0.033 per then-outstanding public share into the Trust Account. Based on filings by Qi Gong, as of May 29, 2026, the Trust Account held approximately $86,699,486.47 across 8,111,568 public shares, resulting in an estimated redemption price of US$10.69. The Board asserts that Proposal 1 and Proposal 2 require the affirmative vote of at least sixty-five percent (65%) of all issued and outstanding ordinary shares. The filing sets June 12, 2026, two business days before the June 16, 2026 virtual meeting, as the hard deadline to tender Public Shares for redemption.

What changed:SBC Medical Group Holdings Incorporated, the successor to Pono Capital Two, called its 2026 annual meeting for 9:00 a.m. Japan Standard Time on July 9, 2026, which is 8:00 p.m. Eastern Time on July 8, 2026, held virtually, record date May 20, 2026 Eastern Time. There were 102,576,943 shares of common stock outstanding and entitled to vote after deducting 270,000 shares held by a wholly-owned subsidiary, and common stock is the only class of voting stock. An Amended and Restated Charter is attached as Annex B in redline form. Why it matters: A single class of 102.6 million voting shares with no dual-class or preferred overhang is an unusually clean capital structure for a de-SPAC successor - each share carries equal weight and no founder block controls the outcome. The charter amendment attached in redline is where the substance lies, since charter changes alter the rights attached to those shares. Scheduling the meeting in Japan Standard Time reflects where the operating business and much of the holder base sit.

●What changed:Definitive Proxy Statement for an Extraordinary General Meeting to approve an amendment extending the deadline to complete a business combination. The company proposes to extend the deadline for completing a business combination from June 20, 2026 to March 20, 2027 (a nine-month extension) and also seeks approval to adjourn the meeting if needed. Why it matters: If the extension is not approved, the company will liquidate and redeem public shares at an estimated ~$10.87 per share (based on trust of ~$250 million as of May 27, 2026); the market close on May 26, 2026 was $10.81. Public shareholders have a redemption right with a deadline of June 11, 2026. The sponsor (25% owner) will vote for the extension, and no definitive agreement with a target has been announced. The outcome determines whether the SPAC continues or liquidates.

What changed:ChargePoint Holdings, Inc. (successor to SPAC Switchback Energy Acquisition Corp) called its annual meeting for Tuesday, July 21, 2026 at 11:00 a.m. Pacific Time as a virtual meeting, record date May 26, 2026, with materials expected to be mailed on or about May 28, 2026. Holders elect three Class III directors to hold office until the 2029 annual meeting and ratify PricewaterhouseCoopers LLP as auditor for the fiscal year ending January 31, 2027. Fiscal 2026 performance RSU awards vest only if the company achieves a specified adjusted EBITDA target for the fiscal year ending January 31, 2027. Why it matters: Routine annual governance with no trust, deadline or redemption relevance to the former Switchback SPAC. The compensation design is the informative part: performance RSUs are conditioned on hitting an adjusted EBITDA target for the year ending January 31, 2027, which confirms the company is still working toward positive adjusted EBITDA rather than reporting it, and that measure excludes stock-based compensation, restructuring severance and facility and contract termination costs. Continued executive turnover is disclosed, including the Chief Legal Officer's resignation in July 2025.

●What changed:Definitive Proxy Statement (DEF 14A) soliciting shareholder approval to amend the charter and trust agreement to extend the deadline for completing a business combination, and disclosing a recently signed merger agreement with ProLogium. TDAC seeks to extend its business combination deadline from June 24, 2026 to June 24, 2027 (up to 12 monthly extensions) via charter and trust agreement amendments. The filing also confirms that on May 27, 2026, TDAC entered into a Business Combination Agreement with ProLogium, with closing expected in H2 2026, subject to conditions including at least $250M available cash and shareholder approval. The sponsor has agreed to fund each monthly extension (the lesser of $200,000 or $0.03 per public share) in exchange for a non-interest bearing promissory note. The Extraordinary General Meeting is set for June 17, 2026; redemption deadline is June 15, 2026. Why it matters: Without approval, TDAC would liquidate by June 24, 2026, making the trust proceeds (~$10.63 per share based on $183.3M trust value) returnable to public shareholders and warrants worthless. The extension is essential to complete the proposed ProLogium merger, which is the only announced deal. The filing provides concrete redemption mechanics, sponsor incentives, and conditions for the merger. It also discloses that the sponsor and initial shareholders hold ~21.26% of voting power and have agreed to vote for the extension and not redeem their shares.

●What changed:T3 Defense Inc. (successor to SPAC Brilliant Acquisition Corp) called a special meeting for June 18, 2026 at 10:00 a.m. ET at virtualshareholdermeeting.com/DFNS2026SM, record date May 21, 2026, when 60,270,525 shares of common stock plus Series B Convertible Preferred were outstanding. Proposal One seeks Nasdaq approval for warrants to acquire 14,084,506 shares at a $2.13 exercise price for five years, subject to adjustment; Proposal Two covers issuance on conversion of the Series B Preferred. The 35,211,265 shares contemplated for resale registration would be about 36.9% of outstanding stock. Why it matters: The company itself quantifies the dilution at about 36.9% of the outstanding share count from the warrant tranche alone, before any Series B Preferred conversion is added on top, and the anti-dilution adjustment language on both the share number and the $2.13 strike means that percentage can grow if the stock falls. Legacy Brilliant SPAC holders bear the full effect. The subsequent annual meeting reported 126,311,902 shares outstanding by July 9, 2026, more than double the 60,270,525 here, showing the dilution converting into actual share count within weeks.

What changed:Planet Labs PBC (successor to SPAC dMY Technology Group IV, ticker DMYQ) set its 2026 annual meeting for Thursday, July 9, 2026 at 10:00 a.m. Pacific Time, entirely virtual, record date May 15, 2026, when 332,899,400 Class A and 23,493,796 Class B shares were outstanding. Fiscal 2026 results disclosed in the proxy: revenue rose 26% to a record $307.7 million from $244.4 million in fiscal 2025; net loss widened to $246.9 million from $123.2 million; adjusted EBITDA swung to a $15.5 million profit from a $10.6 million loss. Why it matters: Routine annual governance with no trust or redemption mechanics left. The numbers are the signal: Planet reached positive adjusted EBITDA of $15.5 million on 26% revenue growth, a genuine operating inflection for a 2021-vintage de-SPAC, while the GAAP net loss doubled to $246.9 million, meaning stock compensation and non-cash charges still dominate the income statement. With 356.4 million shares across both classes, the loss per share burden is spread thin but continued equity issuance remains the funding mechanism.

What changed:Estrella Immunopharma, Inc., successor to TradeUP Acquisition Corp., called a combined 2025/2026 annual meeting for June 29, 2026 at 10:00 a.m. ET, record date May 20, 2026, with 43,034,228 shares outstanding on the record date. Business is limited to ratifying the independent registered public accounting firm for the year ending December 31, 2026 and any other properly brought business; a quorum requires a majority in voting power of outstanding shares. A stockholder list is available for examination from June 19, 2026. Why it matters: No trust, deadline or redemption right remains for UPTD holders. Combining the 2025 and 2026 annual meetings into one mid-2026 event means the company skipped an annual meeting cycle, which is usually a cost and bandwidth signal at a small-cap issuer rather than a governance dispute. The 43,034,228 share count is the base against which any future financing dilution should be measured.

●What changed:Mountain Lake Acquisition Corp. called an extraordinary general meeting for June 12, 2026 at 10:00 a.m. ET to amend its articles and extend the deadline to consummate its initial business combination from June 16, 2026 to September 16, 2026, plus an adjournment proposal. It signed a business combination agreement on October 1, 2025, amended January 13, 2026, with Avalanche Treasury Corporation as Pubco. The registration statement was filed March 27, 2026 and declared effective May 14, 2026; a separate meeting to approve the combination is set for June 4, 2026. Why it matters: This is a three-month backstop extension, not a sign the deal is failing: the registration statement went effective May 14, 2026 and the business combination vote is already scheduled for June 4, 2026, eight days before this meeting. The proxy states that if the combination closes before June 16, 2026 the company will not redeem Class A public shares submitted for redemption solely in connection with this extension meeting, so holders redeeming here risk having that election voided by a timely closing. The board will only adopt the extension if it concludes the deal cannot close by June 16.

●What changed:Bowen Acquisition Corp, a Cayman Islands SPAC, called an extraordinary general meeting for June 11, 2026 at 10:00 a.m. ET, virtually, to approve an extension. The current termination date is June 14, 2026, after which Bowen would be precluded from completing a business combination and required to cease operations, liquidate and dissolve. It has a definitive agreement with Shenzhen Qianzhi BioTechnology Co. Ltd. of the PRC. Based on the trust account as of May 22, 2026, about $7.78 million, the anticipated per-share redemption price is roughly $11.55. Why it matters: The trust floor stands at roughly $11.55 per public share and is payable within ten business days of a failed extension, less up to $100,000 of interest for dissolution expenses and net of taxes, so downside is bounded and near-term for anyone buying below that price. But the trust has shrunk to about $7.78 million in total, meaning prior redemptions have left a very small cash pool, likely too little to fund the Qianzhi combination without substantial outside financing. A June 14, 2026 hard deadline puts the deal three days past the meeting.

What changed:OSR Holdings, Inc. (Nasdaq: OSRH; successor to SPAC Bellevue Life Sciences Acquisition Corp) called an annual meeting for June 18, 2026 at 10:00 a.m., held in person at 10900 NE 4th Street, Suite 2300, Bellevue, Washington, record date May 6, 2026, when 35,104,695 shares of common stock were outstanding. Holders elect seven directors and vote on a charter amendment changing the legal name from OSR Holdings, Inc. to OSR Health, Inc. The meeting is held to satisfy Nasdaq Listing Rule 5620(a). Kuk Hyoun Hwang beneficially owns 13,069,106 shares, or 36.8%. Why it matters: Governance housekeeping rather than a capital event, but two facts matter to holders. Insider concentration is high: a single officer and director holds 36.8% of the 35.1 million shares outstanding, so board composition and any future issuance vote are effectively controlled from inside. The share count also traces sponsor-side conversions from the Bellevue SPAC, including 310,000 private placement rights converted into 31,000 shares and 60,000 private placement warrants exercised into 60,000 shares transferred to BCME under a promissory note.

●What changed:Definitive proxy statement (DEF 14A) soliciting shareholder votes to extend the deadline for Pantages Capital Acquisition Corp. to complete a business combination and to amend the trust agreement. The filing announces an extraordinary general meeting on June 3, 2026, to vote on three proposals: (1) an extension of the business combination deadline from June 6, 2026 to June 6, 2027 via monthly extensions; (2) an amendment to the trust agreement to allow the extension with $0.033/share (up to $60,000/month) deposits; (3) an adjournment proposal. The trust was $91,133,252.83 as of May 20, 2026 ($10.57/share). The closing price on May 20, 2026 was $10.53. Redemption deadline is June 1, 2026. The merger agreement's minimum net tangible assets condition ($5,000,001) was removed via Amendment No. 1. The sponsor may purchase public shares at no more than the redemption price and waive redemption rights. Why it matters: Without an extension, the SPAC would liquidate by June 6, 2026, making all founder shares and rights worthless. Public shareholders face a redemption offer at ~$10.57, which is $0.04 below the recent market price. The removal of the net tangible asset condition for the Horizon Mining business combination suggests the sponsor is prepared to proceed with large redemptions. The filing also warns of potential Nasdaq delisting if too many shares are redeemed.

●What changed:Profusa, Inc. (successor to SPAC NorthView Acquisition Corp) called its 2026 annual meeting for June 23, 2026 at 10:00 a.m. ET, virtual, record date May 12, 2026. Stockholders vote on a charter amendment letting the board effect one or more reverse stock splits at any time on or before June 23, 2028; a Nasdaq Rule 5635(d) proposal for issuance above 19.99% of outstanding common on conversion of a promissory note held by NorthView Sponsor I LLC, modified by an April 24, 2026 conversion agreement; a preferred stock issuance proposal; a convertible notes proposal; and an equity plan amendment. Why it matters: Four separate dilution authorizations sit on one ballot: sponsor note conversion above the 19.99% Nasdaq threshold, a preferred stock issuance, further convertible notes and an enlarged equity plan, backed by a two-year blank-check reverse split authority running to June 23, 2028. The April 24, 2026 modification converts sponsor debt into equity, meaning the SPAC sponsor moves ahead of public holders by turning a loan into stock at the moment the company needs capital. Legacy NorthView holders absorb every layer of that dilution.

●What changed:Origin Materials, Inc. (successor to SPAC Artius Acquisition Inc.) called a special meeting for July 1, 2026 at 8:30 a.m. Pacific Time by webcast, record date May 20, 2026, proxy dated and first mailed May 26, 2026. On May 1, 2026 the company announced that after extensive consideration of strategic alternatives its board had unanimously approved the dissolution and liquidation of Origin Materials under a plan of complete liquidation and dissolution, subject to stockholder approval, and it has discontinued operations in connection with the plan. An adjournment proposal accompanies it. Why it matters: This is a wind-down vote on a business combination completed June 25, 2021 with Micromidas, so legacy Artius SPAC holders who did not redeem are being asked to approve the liquidation of what they exchanged their trust claim for. The financing history explains the outcome: a non-binding term sheet for $20 million announced in November 2025 failed to reach a definitive agreement, which the company disclosed in March 2026, because the lender materially reduced the valuation assumptions underlying the debt. Residual value to common depends on creditors being satisfied first.

●What changed:Greenland Mines Ltd (successor to SPAC Redwoods Acquisition Corp) called a virtual special meeting for June 18, 2026 at 1:00 p.m. ET, record date April 23, 2026, with 121,238,660 shares of common stock outstanding. Proposal 1 is a reverse stock split; the proxy states the board's primary focus in deciding whether to effectuate it will be the ability to obtain and maintain a continued price of at least $1.00 per share on the Nasdaq Capital Market. Proposal 2 is an adjournment if the requisite vote or a quorum is not obtained. Quorum is 33 1/3% of outstanding capital stock. Why it matters: The company states the split's purpose plainly: keeping the stock at or above the $1.00 Nasdaq Capital Market threshold, which means the shares are trading at or near delisting levels. A split preserves proportional ownership but does not add value, and for a company with 121.2 million shares outstanding it typically precedes further issuance. Legacy Redwoods holders who did not redeem their trust shares now hold an equity whose listing depends on a mechanical fix, with the low 33 1/3% quorum making approval easy to secure.

●What changed:All In FutureTech Alliance, Inc. (successor to SPAC Black Ridge Acquisition Corp) called a virtual special meeting for June 1, 2026 at 10:00 a.m. ET, record date May 14, 2026, when 37,016,657 shares of common stock were outstanding; quorum is one-third of shares entitled to vote. The proxy states the company is not eligible for another period of time to regain compliance with the Nasdaq bid price requirement, and that it has not filed its Form 10-K for the period ended December 31, 2025, which Nasdaq noted as an additional basis for delisting the company's securities. Why it matters: Two independent delisting triggers are live at once: the bid price compliance clock has run out with no further cure period available, and the fiscal 2025 Form 10-K is simply not filed, which is a delinquent-filer basis for removal that no reverse split can fix. The board acknowledges the potential harm to stockholders if Nasdaq delists the common stock. For holders this means the equity is on the edge of losing exchange listing and, with no current annual report on file, investors have no audited 2025 financials on which to value it.

●What changed:A Definitive Proxy Statement (DEF 14A) for an Extraordinary General Meeting of Shareholders. The board proposes amending the company's articles to extend the business combination deadline from June 12, 2026 to June 12, 2027, stating it determined there may not be sufficient time before the original cutoff. The board estimates the trust account held approximately $312 million as of the May 6, 2026 record date, projecting a per-share redemption price of approximately $10.85. Shareholders seeking redemption must separate underlying warrants if applicable, submit a written request to transfer agent Continental Stock Transfer & Trust Company, and tender shares via DTC or physically by 5:00 p.m. Eastern Time on June 5, 2026. The board unanimously recommends voting FOR the extension. The sponsor and insiders hold 7,187,500 founder shares (approximately 20.0% of outstanding shares) and intend to vote in favor. Because the extension requires a two-thirds special resolution, the company states it needs 16,770,834 public shares (approximately 58.3% of the 28,750,000 public shares) voted in favor to meet the threshold. The filing discloses the sponsor may purchase public shares to reduce redemptions, provided those shares are not voted FOR the proposal. The sponsor continues to receive $10,000 per month under an administrative services agreement until earlier of a transaction or liquidation.

●What changed:DEF 14A Definitive Proxy Statement convened by the Board of Flag Ship Acquisition Corporation to solicit shareholder votes at an Extraordinary General Meeting on charter amendments and meeting adjournment procedures. The filing outlines mechanics for extending the business combination deadline from June 20, 2026 to June 20, 2027 via up to twelve one-month extensions exercisable without further shareholder votes upon payment of a monthly extension fee. The fee requires the Sponsor to deposit into the Trust Account the lesser of $60,000 for all remaining public shares or $0.033 per remaining public share, commencing June 20, 2026. The Board disclosed a Trust Account balance of approximately $33,707,330 as of the May 13, 2026 record date, projecting a redemption price of approximately $11.01 per share against a record date closing market price of $10.98. Public shareholders may irrevocably tender shares or deliver them electronically via DWAC by 5:00 p.m. Eastern Time on June 9, 2026, regardless of how they vote. Approval requires a special resolution of not less than two-thirds of votes cast. The Sponsor holds 1,963,000 ordinary shares (approximately 39.06%), intends to vote in favor, and noted potential undisclosed private purchases or incentive arrangements to discourage redemptions. The Company also confirmed approximately $1,446,751 in principal owed on a Sponsor promissory note as of December 31, 2025, and warned that failure to approve triggers liquidation on June 20, 2026, with rights expiring worthless and founder/private shares excluded from distributions. Why it matters: According to the Board, the extension enables continued negotiations following the mutual termination of an October 21, 2024 merger agreement with Great Rich Technologies Limited (terminated April 18, 2025) and a subsequent agreement with Great Future Technology Inc. (terminated May 3, 2026), neither of which required termination fees. Management cites a May 8, 2026 letter of intent with Bluechip & Co. Holdings granting a ninety-day exclusive negotiation period as the basis for seeking additional time. The proxy details executive compensation risks and conflicts, noting the Sponsor’s substantial foreign ties could restrict targets subject to CFIUS review, while prolonged search activity raises potential Investment Company Act classification risks. Director biographies confirm continuity with Chairman and CEO Matthew Chen, CFO Luhuan Zhong, and independent directors Shan Cui, Pai Liu, and Wen He. Tax counsel disclosures emphasize complex U.S. federal income treatment for redeeming shareholders, particularly Passive Foreign Investment Company (PFIC) status implications and the necessity of timely Qualified Electing Fund (QEF) elections to avoid penalty tax allocations.

What changed:Royalty Management Holding Corporation (successor to SPAC American Acquisition Opportunity Inc.) called its annual shareholder meeting for Tuesday, June 30, 2026 at 10:00 a.m. ET, held in person at the company's headquarters, 12115 Visionary Way, Suite 174, Fishers, Indiana, record date May 4, 2026. The sole substantive item disclosed is approval of CM3 Advisory as independent registered public accounting firm for calendar 2026. Voting occurs by mail or during the meeting itself. Directors received 25,000 stock warrants each year for board service, valued using the Black-Scholes model. Why it matters: Ordinary annual governance with no trust, deadline or redemption consequence for legacy American Acquisition Opportunity holders. Two mechanical points matter. The meeting is in person in Indiana with voting only by mail or attendance, no virtual option, which materially suppresses retail participation. And directors are paid in 25,000 warrants per year rather than cash or restricted stock, a structure that adds share count each year and whose reported value is an amortized Black-Scholes figure rather than cash actually paid.

●What changed:Definitive proxy statement (DEF 14A) for an extraordinary general meeting in lieu of an annual meeting, filed by Melar Acquisition Corp. I, to solicit shareholder approval for three proposals: an extension amendment, auditor ratification, and an adjournment provision. The filing sets a shareholder meeting for June 16, 2026 to vote on extending the business combination deadline from June 20, 2026 to December 20, 2026 via up to six monthly extensions, with a redemption deadline for public shareholders of June 12, 2026 at a per-share price of approximately $10.852 based on a trust account of $173.6 million as of May 14, 2026. The sponsor or its designees (including Everli) will loan the SPAC up to $0.02 per non-redeemed public share per month to fund the extension. The SPAC is pursuing the Everli Business Combination under a merger agreement dated July 30, 2025 (as amended). Why it matters: This filing directly affects the redemption calendar, trust value, and timeline for the proposed business combination. Shareholders must decide whether to redeem by June 12, 2026 or risk the extension potentially failing and leading to liquidation if not approved. The extension loans are small relative to trust size, and the sponsor's commitment signals continued deal pursuit but also risk if redemptions are high. The trust value per share ($10.852) is below the stated $10.93 from earlier data, indicating interest has been used for taxes. Failure to pass the extension would force liquidation by June 20, 2026.

●What changed:Perceptive Capital Solutions Corp called an extraordinary general meeting for June 10, 2026 at 10:00 A.M. Eastern Time at the offices of Cooley LLP to extend its Termination Date from June 13, 2026 to June 13, 2027 by special resolution amending its Memorandum and Articles of Association. The extension is sought to complete the business combination entered December 5, 2025 with StarNet Merger Sub I, Corp. and StarNet Merger Sub II, LLC. Without it the board believes PCSC would be precluded from completing a business combination and would be forced to liquidate. Why it matters: A full twelve-month extension is unusually long and means holders who stay carry deal risk to June 2027 - the proxy discloses no contribution accreting the trust in exchange. The adjournment provision is the telling detail: the meeting can be adjourned if redemptions would leave PCSC below Nasdaq's continued listing requirements, which flags that heavy redemption is expected. Redeeming at the trust value remains the certain alternative to a deal signed six months earlier and still unclosed.

●What changed:Origin Materials, Inc. (successor to SPAC Artius Acquisition Inc.) filed this definitive proxy on May 14, 2026 for a special meeting by live webcast at 8:30 a.m. Pacific Time on a date left blank in the document, record date May 20, 2026. On April 28, 2026 the board unanimously determined dissolution and liquidation was advisable, and on May 1, 2026 the company announced approval of a plan of complete liquidation and dissolution subject to stockholder approval. The Micromidas business combination closed June 25, 2021. Why it matters: The substance is a liquidation vote for a 2021 de-SPAC: stockholders are asked to approve winding the company up rather than any operating or sale alternative. The blank meeting date in the filed document means holders must track a later notice for the actual voting deadline, and the record date of May 20, 2026 already sets who is entitled to vote. For legacy Artius holders the trust redemption right was surrendered at closing, so recovery now depends entirely on residual assets after creditors, not on any per-share trust floor.

●What changed:Definitive proxy statement (DEF 14A) for an extraordinary general meeting of shareholders to approve an amendment to the company's articles of association to extend the deadline to complete an initial business combination from June 5, 2026 to March 5, 2027, and an adjournment proposal. The Board proposes to extend the business combination deadline by up to nine months (to March 5, 2027). If approved, the sponsor (Tavia Sponsor Pte. Ltd.) or its designees will deposit into the trust account as a loan, on each of the current termination date and the 5th day of each subsequent month, the lesser of $60,000 or $0.03 per public share outstanding. The company has not independently verified the sponsor's ability to make these contributions. Public shareholders may redeem their shares at an estimated $10.59 per share (based on $121.8 million in the trust as of March 31, 2026). The redemption deadline is 5:00 p.m. Eastern Time on May 29, 2026. The Board unanimously recommends a vote FOR the extension. The company states it is 'currently in serious discussions with a potential business combination target' but believes there will not be sufficient time before the current deadline. Insiders (initial shareholders, officers, directors, and EBC) holding approximately 27.8% of outstanding shares are expected to vote FOR. They have waived redemption rights on founder shares, EBC founder shares, and private shares. Why it matters: This filing sets the terms and timeline for a critical extension vote. If the extension is not approved, the SPAC will liquidate by June 5, 2026, and public shareholders will receive their pro rata trust share (~$10.59). If approved, the SPAC gains up to nine more months to complete a deal, but the trust may be reduced by redemptions, and the sponsor's ability to fund monthly contributions is unverified. The board's recommendation and insider voting intentions are disclosed, as are potential conflicts of interest. The trust value per share of $10.59 is slightly below the $10.60 market price on May 11, 2026, meaning redemption yields a small discount. This is a material event for SPAC investors evaluating whether to redeem or hold.

What changed:Navitas Semiconductor Corporation (successor to SPAC Live Oak Acquisition Corp II) set its annual meeting for Thursday, June 25, 2026 at 8:00 a.m. Pacific Time at virtualshareholdermeeting.com/NVTS2026, record date April 28, 2026, with KPMG LLP up for ratification as auditor for the year ending December 31, 2026. Pay-versus-performance disclosure shows a 2025 net loss of $116.95 million against an $84.60 million loss in 2024, with total shareholder return of $203.42 per $100 invested versus $101.71 a year earlier. Ownership percentages are based on 233,713,166 Class A shares. Why it matters: Routine annual governance; the SPAC trust and redemption rights ended at the 2021 combination. The disclosed figures show the familiar post-SPAC pattern: the net loss widened by roughly 38% to $116.95 million in 2025 while the stock doubled, lifting total shareholder return to $203.42 per $100, so the valuation rests on future design wins rather than current earnings. Long-term incentive options in tranches 6 through 10 do not vest until the fourth anniversary of the December 29, 2025 grant date, deferring but not removing that dilution.

●What changed:A definitive proxy statement (SEC Form DEF 14A) convened by Bayview Acquisition Corp to solicit shareholder votes at an extraordinary general meeting on May 28, 2026, regarding an extension amendment proposal, a trust agreement amendment proposal, and an adjournment proposal. The Board proposes extending the business combination deadline from June 19, 2026 to December 19, 2026 via a special resolution requiring two-thirds of votes cast, paired with a Trust Agreement Amendment permitting up to six consecutive one-month extensions. According to the filing, each extension requires sponsors to deposit $50,000 into the trust account five days in advance in exchange for a non-interest-bearing, unsecured promissory note payable upon a business combination or forfeited upon liquidation if outside funds do not exist. Public shareholders may elect to redeem shares regardless of their vote, provided written requests are submitted by 5:00 p.m. ET on May 26, 2026, subject to a Charter provision stating redemptions cannot cause net tangible assets to fall below $5,000,001 after deferred underwriting commissions, nor exceed 15% of outstanding public shares per shareholder group without prior consent. On the May 4, 2026 record date, the trust account held approximately $12,103,085.50, which the board calculates yields a pro rata redemption price of approximately $12.03 per share against a Nasdaq closing price of $12.00. Initial shareholders controlling 1,732,500 ordinary shares (approximately 63.3% of the outstanding class) state they intend to vote in favor and have waived any right to participate in liquidating distributions. The Board confirms both extension and trust amendments are mutual conditions for implementation.

●What changed:Revelation Biosciences, Inc. (successor to SPAC Petra Acquisition Inc.) called its 2026 annual meeting for June 24, 2026 at 12:00 p.m. ET by Zoom, record date April 30, 2026, when only 3,908,420 shares of common stock were outstanding. The proxy discloses three reverse stock splits in twelve months: 1-for-16 effected January 28, 2025, after which Nasdaq confirmed on February 19, 2025 that minimum bid price compliance was regained; 1-for-3 effected July 7, 2025 after a June 23, 2025 special meeting; and 1-for-4 effected January 28, 2026. Why it matters: Three reverse splits inside a single year, each undertaken to regain or hold the Nasdaq minimum bid price, is the clearest possible evidence that the share price keeps falling back below $1.00 after every mechanical fix. The share count is down to 3.9 million, so each new financing at a depressed price is proportionally devastating to existing holders and likely forces yet another split. Legacy Petra SPAC holders who converted at the business combination have watched their position compressed by a cumulative factor measured in the hundreds.

What changed:Skillsoft Corp. (successor to SPAC Churchill Capital Corp II, ticker CCX) set its 2026 annual meeting for Thursday, June 25, 2026 at 3:00 p.m. ET at virtualshareholdermeeting.com/SKIL2026, record date May 4, 2026. Fiscal 2026 highlights disclosed: total GAAP revenue of $513 million against $531 million a year earlier; GAAP net loss of $140 million versus $122 million; GAAP net loss per share of $16.27 versus $14.87; cash, cash equivalents and restricted cash of $104.5 million at January 31, 2026; operating cash flow of $25.1 million and non-GAAP free cash flow of $6.5 million. Why it matters: Routine governance, but the disclosed financials define the risk for anyone still holding the former Churchill Capital II position: revenue declined roughly 3% to $513 million while the net loss deepened to $140 million, and a $16.27 loss per share against a January 30, 2026 NYSE close of $9.05 means the annual loss exceeds the entire market value of a share. The offsetting fact is real liquidity, $104.5 million of cash and positive free cash flow of $6.5 million, so the losses are largely non-cash rather than an immediate solvency threat.

●What changed:definitive proxy statement (DEF 14A) for an extraordinary general meeting of shareholders of Rising Dragon Acquisition Corp., a blank-check company searching for a business combination. The filing seeks shareholder approval to extend the deadline to complete a business combination, from the current Termination Date of July 15, 2026, to a new Extended Date of October 15, 2027. This would require: (1) approving an amendment to the company's charter to allow up to fifteen additional one-month extensions; (2) amending the trust agreement to reduce the monthly extension fee to the lesser of $100,000 or $0.033 per remaining public share; and (3) authorizing an adjournment of the meeting if necessary. As of May 7, 2026, the per-share redemption price is approximately $10.63, the trust account holds marketable securities with a fair value of approximately $45.3 million, and the stock closed at $7.63 per share. The filing notes that for the November 20, 2025 Business Combination EGM, shareholders of 5,049,309 shares voted to approve the HZJL business combination, and 5,715,609 shares were tendered for redemption.

What changed:SHF Holdings, Inc. (successor to SPAC Northern Lights Acquisition Corp) called its 2026 annual meeting for June 17, 2026 at 7:30 a.m. Mountain Daylight Time by live webcast at virtualshareholdermeeting.com/SFHS2026, record date April 30, 2026. The capital structure disclosed includes 1,250,000 authorized shares of convertible preferred stock with 111 outstanding and 35,000 authorized shares of Series B Preferred with 29,501 issued and outstanding; only common holders vote on the matters presented. The audit committee held six meetings during the year ended December 31, 2025. Why it matters: Governance-only filing with no residual trust or redemption rights from the Northern Lights SPAC, whose business combination closed September 28, 2022. The structural point for common holders is that 29,501 Series B Preferred shares are outstanding against a 35,000 authorization and carry no vote at this meeting, so a preferred block sitting senior to common in liquidation has been issued without common holders having a say. Executive severance terms disclosed include six months of supplemental severance for Mr. Dennedy.

●What changed:Aspire Biopharma Holdings, Inc. (successor to SPAC PowerUp Acquisition Corp) called a special meeting for June 9, 2026 at 10:00 a.m. ET, held in person at 4626 N 300 W, Suite 350, Provo, Utah, record date April 13, 2026. The warrant issuance proposal asks stockholders to approve issuance of common stock on exercise of warrants, including all warrant shares in excess of 19.99% of the common stock outstanding on April 22, 2026, at an aggregate exercise price of $0.00001 per warrant share, covering 2,346,531 shares subject to adjustment for splits and similar transactions. Why it matters: An exercise price of $0.00001 per share means these are effectively free shares: the holder pays nothing meaningful and existing stockholders absorb the entire issuance. Because the request expressly covers the portion above 19.99% of shares outstanding, the dilution is designed to exceed the Nasdaq threshold that normally requires a separate vote. The warrant terms also impose cash liquidated damages on the company for every $1,000 of undelivered warrant shares if it misses the delivery date, a penalty that falls on the same shareholders being diluted.

●What changed:CXApp Inc. (successor to SPAC KINS Technology Group, whose merger closed March 14, 2023) called its 2026 annual meeting for June 16, 2026 at 2:00 p.m. Pacific Time in virtual format, record date April 17, 2026, when 69,015,433 shares of common stock were outstanding. Holders elect Khurram Sheikh and George Mathai as Class III directors serving until the meeting following fiscal year 2028, and vote on a Nasdaq 20% proposal under Listing Rule 5635(d) to approve issuance of common stock, or securities convertible into or exercisable for common stock, in one or more private placements. Why it matters: The Nasdaq 20% proposal is the item with money attached: approval gives management standing authority to place shares or convertible securities above the 20% threshold in one or more private placements without a further vote. Against 69.0 million shares outstanding that is at least 13.8 million shares of pre-cleared dilution and potentially far more, since convertible instruments typically price at a discount to market. Legacy KINS SPAC holders bear it. The remaining items, two Class III director elections, are routine.

●What changed:Definitive proxy statement for an extraordinary general meeting to vote on an extension amendment to the company's articles of association. The SPAC proposes to extend the deadline to complete a business combination from 18 months (June 23, 2026) to 24 months (December 23, 2026) after the IPO. The trust account had approximately $121,936,241.23 as of May 1, 2026, implying a per-share redemption price of about $10.60. The sponsor, holding 23.1% of shares, will vote in favor. Redemption deadline is 5:00 p.m. ET on June 16, 2026, with the meeting on June 18, 2026. No business combination has been announced; the SPAC remains in the searching phase. Why it matters: This extension vote is existential: if not approved, the SPAC will liquidate on June 23, 2026. The trust value ($10.60 per share) is above the initial $10.00, providing a modest premium for redeeming shareholders. The extension gives the sponsor more time to find a target, but the filing also includes risk factors (e.g., CFIUS review, potential redemptions leaving insufficient funds). The outcome will determine whether the SPAC continues or dissolves.

What changed:Xos, Inc. (successor to SPAC NextGen Acquisition Corp) called its 2026 annual meeting for Tuesday, June 23, 2026 at 11:00 a.m. Pacific Time by webcast at virtualshareholdermeeting.com/XOS2026, record date April 24, 2026, when 12,056,211 shares of common stock were issued and outstanding, one vote per share, with a majority required for quorum. Alongside routine items the agenda includes a proposal relating to a share issuance. Former director Ms. Ingargiola resigned effective June 24, 2025 and standing committees were reconstituted effective January 1, 2026. Why it matters: Ordinary annual governance for a de-SPAC with no trust or redemption exposure remaining. The number that stands out is the share count: 12,056,211 shares outstanding for a company that went public through a 2021 SPAC implies heavy reverse-split compression, which usually follows sustained trading below the Nasdaq minimum bid price. The available text does not describe the terms of the issuance proposal on the agenda, so its dilutive scale cannot be assessed from this document alone and holders should read the full proposal.

●What changed:Skillz Inc., the successor to Flying Eagle Acquisition Corp., called its 2026 annual meeting for June 18, 2026 at 10:00 a.m. Pacific Time by virtual web conference, record date April 24, 2026, with director elections and ratification of Deloitte & Touche LLP for the fiscal year ending December 31, 2026. The pay-versus-performance table reports a 2025 net loss of $70,408 thousand and total shareholder return of $0.95 per $100 invested. Director RSU grants were cut to a $250,000 target value from $400,000 in 2024, sized on the fifteen-trading-day NYSE VWAP and vesting over four years. Why it matters: A total shareholder return of $0.95 for every $100 invested means holders have lost more than 99% of their capital since the measurement date, while the company still lost $70.4 million in 2025 - among the worst outcomes in the de-SPAC cohort. Cutting director equity from $400,000 to $250,000 acknowledges it. Sizing those RSUs off a trailing VWAP still means a lower price produces more shares, so dilution accelerates as the stock falls further.

What changed:Evolv Technologies Holdings set its annual meeting for Thursday, June 18, 2026 at 10:00 a.m. ET by live webcast, record date April 24, 2026. The letter reports 2025 results: annual recurring revenue up 21% to $120.5 million from $99.4 million in 2024; net loss narrowed to $33.1 million, or $0.20 per diluted share, from $54.0 million and $0.34 in 2024; and adjusted EBITDA swung to positive $11.1 million from negative $21.0 million. The company attributes part of the change to a mid-2025 shift to directly fulfilling the hardware portion of subscription orders. Why it matters: For a de-SPAC successor the relevant floor is operating cash generation, not a trust: adjusted EBITDA turning from negative $21.0 million to positive $11.1 million in a single year, with the net loss halved, materially reduces the odds of a dilutive rescue financing. Board turnover is disclosed alongside - Bilal Zuberi resigned February 10, 2026 and Henrik Kuhl was appointed February 12, 2026 - so the audit and compensation committees were reconstituted just before this proxy.

What changed:Archer Aviation Inc., the successor to Atlas Crest Investment Corp., set its annual meeting for Friday, June 26, 2026 at 12:00 p.m. Pacific Time, virtual at virtualshareholdermeeting.com/ACHR2026, record date Tuesday, April 28, 2026. The proxy details the 2021 Founder Grant of 20,009,224 PSUs to Mr. Why it matters: The dilution here is contractual and automatic: an evergreen reserve adding up to 9,938,118 shares a year through 2031 plus a 20,009,224-share founder PSU package means the share count grows every January without a shareholder vote. Non-employee directors also receive a $200,000 Initial Equity Grant. For holders the practical read is that per-share value must outrun a structurally expanding denominator.

What changed:SoFi Technologies, Inc. (successor to SPAC Social Capital Hedosophia Holdings Corp V) called its 2026 annual meeting for Wednesday, June 17, 2026 at 7:00 a.m. Pacific Time, virtually, record date April 20, 2026. The proxy reports 2025 results: record total net revenue of $3.6 billion, up 35% year over year, adjusted net revenue also $3.6 billion, up 38%; net income of $481.3 million; adjusted EBITDA of $1.1 billion; and 13.7 million members at year end, 35% growth. New non-employee directors receive an initial RSU grant valued at $250,000. Why it matters: Routine annual governance, but the underlying figures make SoFi the outlier of the SPAC cohort: $481.3 million of GAAP net income and $1.1 billion of adjusted EBITDA on $3.6 billion of revenue, with 35% growth in both revenue and members. For investors assessing whether de-SPACs can produce durable businesses, this is the affirmative case, and it means the equity is valued on earnings rather than on a trust floor or a promise. Director equity priced off a trailing 30-day average limits grant-date timing advantages.

What changed:Sable Offshore Corp., the successor to Flame Acquisition Corp., called its 2026 annual meeting for June 10, 2026 at 8:00 a.m. Eastern Daylight Time by online webcast, record date April 20, 2026, with the Notice expected to be mailed on or about April 30, 2026. Holders elect one Class II director, Gregory Pipkin, to a term expiring in 2029 and ratify Ham, Langston & Brezina, L.L.P. for the fiscal year ending December 31, 2026. Why it matters: The going-concern language attached to the SPAC itself before the November 2, 2022 merger agreement is standard for a blank-check company approaching its deadline and does not carry into the operating business. What matters now is that only one director stands for election in a staggered structure, so holders can turn over at most a third of the board a year. The Flame trust was released at closing, leaving no redemption right or floor.

What changed:Better Home & Finance Holding Company, the successor to Aurora Acquisition Corp., called its 2026 annual meeting for Wednesday, June 10, 2026 at 12:00 p.m. ET, virtual at virtualshareholdermeeting.com/BETR2026, record date April 15, 2026. The proxy discloses that in connection with the Closing, Better awarded transaction bonuses totalling $17 million in the aggregate to certain employees in September 2023, including $9.7 million to Mr. Garg and $200,000 to Ms. Tuffin, each payable in two installments. Why it matters: The $17 million of transaction bonuses, of which $9.7 million went to a single executive, was cash paid out of the de-SPAC proceeds rather than retained for the operating business - a direct transfer from the trust the Aurora shareholders funded to insiders at closing. Two board resignations within five months compound the governance question this annual meeting puts to holders.

What changed:GeneDx Holdings Corp., successor to CM Life Sciences, Inc., called a virtual annual meeting for June 18, 2026 at 9:00 a.m. ET, record date April 20, 2026, with materials distributed on or about April 30, 2026. The compensation discussion reports full-year 2025 results: exome and genome test revenue grew 54% year over year to $360.3 million, or 58% excluding a one-time 2024 benefit; adjusted gross margin expanded to 71% from 65% in 2024; and adjusted net income reached $41.8 million against $9.4 million for full year 2024. The company states it achieved its 2025 performance target goals. Why it matters: Revenue growth of 54% to $360.3 million with adjusted net income more than quadrupling to $41.8 million puts GeneDx in the small minority of de-SPAC successors operating profitably on an adjusted basis. For holders that removes the financing overhang that dominates this cohort - the company is not dependent on issuing stock to fund the next year, and the 71% adjusted gross margin gives operating leverage room as volumes grow.

What changed:AleAnna, Inc., the successor to Swiftmerge Acquisition Corp., called its 2026 annual meeting for Friday, June 26, 2026 at 11:00 am Eastern Time by live webcast, record date April 28, 2026, with materials expected on or about May 8, 2026. At the record date there were 66,934,400 shares outstanding, comprising 40,940,000 Class A shares and 25,994,400 Class C shares. Holders re-elect Curtis Hebert Jr. and William K. Dirks as Class II directors to 2029 and ratify Deloitte & Touche LLP for the fiscal year ending December 31, 2026. Why it matters: Class C shares number 25,994,400 against a 40,940,000 Class A float, so roughly 39% of the vote sits outside the public shares - the legacy structure from the Swiftmerge de-SPAC. The sponsor promissory note carried over from September 2023 is a claim ahead of equity that survived the closing. Investor lock-ups ran only to December 13, 2025, so that supply is already free to trade against the current count.

What changed:Grindr Inc. (successor to SPAC Tiga Acquisition Corp) called its 2026 annual meeting for June 2, 2026 at 8:00 a.m. ET by live webcast, record date April 9, 2026. Holders elect eight director nominees to serve until the next annual meeting, ratify Ernst & Young LLP as auditor for the fiscal year ending December 31, 2026, and vote on an amendment and restatement affecting the 2020 Equity Incentive Plan. The proxy reports 177,218,700 shares of common stock outstanding and a per-share closing price on the NYSE of $11.99, with option expiration dates ranging into October 2027. Why it matters: Routine annual governance; the Tiga trust and redemption rights ended with the business combination completed under the merger agreement as amended October 5, 2022. The item carrying economic cost is the equity plan amendment and restatement, which increases the share reserve available for grant against 177.2 million shares outstanding at an $11.99 NYSE price, so the dilution is measured in real market value rather than in an underwater currency. An annually elected board, rather than a staggered one, leaves directors accountable each year.

What changed:Sky Harbour Group Corporation, the successor to Yellowstone Acquisition Co, called its annual meeting for Thursday, June 18, 2026 at 10:30 a.m. Eastern Time in person at its offices at Westchester County Airport, White Plains, New York, record date April 21, 2026, with Class A and Class B common stock voting. The Board met four times during the fiscal year ended December 31, 2025. Mr. Jackson served as Audit Committee chair until his resignation effective December 31, 2025, with Mr. Moelis now chair. Why it matters: Class B holders control 42.0 million shares, and 15.8 million further Class A shares sit behind warrants - a dilution block larger than most of the operating share base, exercisable at the holders' option. The audit committee chair resigning at year end, with the board meeting only four times, is thin oversight for a capital-intensive hangar developer. An in-person-only meeting at an airport terminal also limits practical participation.

What changed:Bakkt, Inc. (successor to SPAC VPC Impact Acquisition Holdings) called its annual meeting for Tuesday, June 23, 2026, with the board fixing April 24, 2026 as the record date. The proxy discloses continuing committee turnover: Sean Collins ceased serving on the compensation committee effective April 10, 2025, Jill Simeone resigned from the board on November 7, 2025 and left the committee then, and Michael Alfred joined effective September 17, 2025. The Form 10-K for the year ended December 31, 2025 was filed March 19, 2026. Why it matters: Ordinary annual governance for a completed de-SPAC; the VPC Impact trust and redemption rights ended at the 2021 combination. The relevant pattern for holders is compensation committee instability, with three separate membership changes across 2025, at a company whose executive ranks have also turned over repeatedly, as the pay-versus-performance tables covering multiple principal executive officers across 2024 and 2025 indicate. Frequent committee reconstitution weakens continuity in setting pay against performance.

What changed:Hagerty, Inc. (successor to SPAC Aldel Financial) called its 2026 annual meeting for Tuesday, June 9, 2026 at 11:00 a.m. ET by live webcast, record date April 10, 2026, when about 101,792,016 Class A shares, 241,552,156 Class V shares and 8,483,561 Series A Convertible Preferred shares were outstanding. Class A carries one vote per share, Class V ten votes per share. On April 15, 2026 the company announced Michael Heaton resigned effective April 13, 2026 and that Markel Group exercised its Investor Rights Agreement right to nominate Henrik Bjornstad. Why it matters: Routine annual governance, but the voting math is the point for public holders: 241.6 million Class V shares at ten votes each control roughly 2.4 billion votes against about 101.8 million votes from Class A, so the Class A float holds around 4% of voting power and the annual election is effectively decided by the insider class. Markel's contractual right to name a director, exercised in April 2026, further allocates board seats outside the shareholder vote. The 8.5 million convertible preferred shares add a senior claim above Class A.

What changed:Zura Bio Limited, the Cayman successor to JATT Acquisition Corp, called a virtual annual general meeting for Wednesday, June 17, 2026 at 12:00 p.m. ET, record date Monday, April 20, 2026, using Full Set Delivery of paper proxy materials. There were 94,880,710 Class A ordinary shares issued and outstanding on the record date, and quorum requires holders of at least a majority of those shares. Holders vote to elect directors, to ratify WithumSmith+Brown, PC for the fiscal year ended December 31, 2026, and to approve an amended and restated 2023 equity plan. Why it matters: The amended 2023 Plan is written so its share reserve grows in proportion to total economic capitalization, which means the equity pool expands automatically as the company issues stock - dilution that compounds with any future raise rather than requiring a fresh shareholder vote. Against 94.9 million Class A shares at a $5.37 reference price, that is the main structural item on the ballot; no trust or redemption right survives from the JATT SPAC.

What changed:Scilex Holding Company (successor to SPAC Vickers Vantage Corp, ticker VCKA) called its 2026 annual meeting for Wednesday, June 24, 2026 at 9:00 a.m. Pacific Time, held virtually, record date April 28, 2026, with the record date share count given as 8,491,267. A quorum requires holders of a majority of the voting power of the outstanding common stock and Series A Preferred Stock voting together. Each current non-employee director held options on 20,000 shares at December 31, 2025: Dr. Chun, Mr. Followwill and Dr. Wu. Dr. Navani resigned from the board effective September 22, 2025. Why it matters: Routine annual governance with no trust or redemption mechanics left from the Vickers SPAC. The capital structure is the item to watch: Series A Preferred votes together with common for quorum and voting purposes, so a preferred class senior in liquidation also carries influence over board outcomes, and the very small common share count implies prior reverse-split compression. Director option holdings of 20,000 shares each are immaterial against that base, so the dilution risk sits with the preferred and any future issuance rather than with board pay.

What changed:AlTi Global, Inc. (successor to SPAC Cartesian Growth Corp) called its 2026 annual meeting for June 17, 2026 at 10:00 a.m. ET, a completely virtual meeting with registration at virtualshareholdermeeting.com/ALTI2026, record date April 20, 2026, when 151,617,840 shares of common stock were outstanding and entitled to vote. Business includes auditor ratification. The business combination closed January 3, 2023. Nazim Cetin was appointed to the board on July 31, 2024 pursuant to the Allianz Investor Rights Agreement. Why it matters: Routine annual governance with no trust or redemption exposure remaining from the Cartesian Growth SPAC. The governance fact with real weight is the Allianz Investor Rights Agreement, under which a strategic investor holds a contractual right to nominate a director, seated July 31, 2024. Board seats granted by contract rather than by shareholder vote reduce the practical effect of the annual election for the 151.6 million public shares, and typically accompany a preferred or structured investment whose terms sit ahead of common equity.

What changed:The Oncology Institute, Inc., the successor to DFP Healthcare Acquisitions Corp., noticed its annual meeting for Wednesday, June 17, 2026 at 11:00 a.m. Pacific Time as a fully virtual meeting at proxydocs.com/TOI, record date April 24, 2026, with each share of common stock carrying one vote. The proxy recaps that the business combination with TOI Parent, Inc. closed November 12, 2021 under a merger agreement dated June 28, 2021 among DFP Healthcare Acquisitions Corp., Orion Merger Sub I, Orion Merger Sub II and TOI Parent. Why it matters: Routine annual governance almost five years after the DFP trust was released - no redemption right, deadline or floor remains for former SPAC holders. The single number worth carrying forward is the $174.51 TSR value for 2025 against a much weaker 2024 comparison, which shows the equity re-rating well after the de-SPAC even as the company continued to report a net loss.

●What changed:P3 Health Partners Inc., the successor to Foresight Acquisition Corp., noticed its annual meeting for Tuesday, June 9, 2026 at 9:00 a.m. Pacific Time by webcast, record date April 10, 2026, with Class A and Class V common stock voting together as a single class. Proposal 4 asks holders to approve, under Nasdaq Listing Rule 5635(d), the issuance of up to 3,341,130 shares of Class A common stock on exercise of warrants held by VBC Growth SPV 5, LLC, issued in a May 29, 2025 financing by subsidiary P3 Health Group, LLC that also included an unsecured promissory note. Why it matters: A 1-for-50 reverse split in April 2025 followed by a Nasdaq 20% Rule vote on warrants tied to an unsecured promissory note is the signature of a company financing itself off the balance sheet at the shareholder's expense. Approval releases up to 3,341,130 new Class A shares against a post-split base already compressed fifty-fold, and rejection leaves the warrants unexercisable, which typically puts the underlying note financing in dispute.

What changed:SAB Biotherapeutics, Inc. (successor to SPAC Big Cypress Acquisition Corp) called its 2026 annual meeting for Thursday, June 18, 2026 at 10:00 a.m. ET at virtualshareholdermeeting.com/SABS2026, exclusively online with no physical meeting, record date April 20, 2026. Holders elect Katie Ellias, David Link and Andrew Moin as Class II directors for three-year terms and ratify EisnerAmper LLP as auditor for the fiscal year ending December 31, 2026. Series A Preferred outstanding on the record date is generally entitled to vote alongside common. Why it matters: Routine annual governance with no trust, extension or redemption mechanics left from the Big Cypress SPAC. The one structural item for common holders is that Series A Preferred votes generally alongside common stock, so a preferred block that ranks ahead of common in liquidation also carries voting power on director elections and any future proposals, diluting the influence of the public float. A staggered board with three-year Class II terms further limits how quickly shareholders could change board composition.

What changed:Semnur Pharmaceuticals, Inc., the successor to Denali Capital Acquisition Corp., noticed its 2026 annual meeting for Thursday, June 25, 2026 at 9:00 a.m. Pacific Time, held virtually, record date April 28, 2026. Quorum requires a majority of the voting power of the outstanding Common Stock and Series A Preferred Stock voting together, and the proxy reports 230,209,142 shares on the record date. The business combination closed September 22, 2025 under an agreement and plan of merger dated August 30, 2024, as amended by Amendment No. 1 dated April 16, 2025 and a later Amendment No. 2. Why it matters: This is the first annual meeting after the September 22, 2025 closing, so the Denali trust has already been released and no redemption right remains. The structural point for holders is that Series A Preferred votes alongside common on quorum and on matters generally, meaning the post-deal preferred investors hold voting weight in addition to whatever liquidation preference they carry ahead of the 230.2 million common shares.

What changed:IonQ, Inc. (successor to SPAC dMY Technology Group III) called its 2026 annual meeting for Tuesday, June 16, 2026 at 12:00 PM ET, virtually by live audio webcast, record date April 17, 2026. Business includes director elections, auditor ratification and an advisory vote on 2025 executive compensation. The nominating committee, under a charter meeting NYSE standards, held six meetings in 2025, and on August 12, 2025 the board established a product and strategy committee. Vesting of Mr. Kramer's securities was accelerated on his September 4, 2025 termination. Why it matters: Ordinary annual governance with no residual trust or redemption rights from the dMY III SPAC. Two governance signals are worth noting for holders: the board created a dedicated product and strategy committee in August 2025, indicating direct board involvement in technical roadmap decisions at a company still pre-commercialization in most lines, and executive turnover continued with accelerated equity vesting on a September 2025 termination, which pulls dilution forward rather than forfeiting unvested shares back to the pool.

What changed:Aeva Technologies, Inc., successor to InterPrivate Acquisition Corp., called its 2026 annual meeting for Thursday, June 18, 2026 at 10:00 a.m. Pacific Time as a virtual meeting at virtualshareholdermeeting.com/AEVA2026. The pay-versus-performance table reports a 2025 net loss of $145 million against $152 million in 2024, with total shareholder return improving to $195.29 per $100 invested from $69.85. Directors Christopher Eberle and Erin L. Polek resigned effective May 1, 2025 and March 31, 2025. Non-employee directors each held 5,968 RSUs at year end. Why it matters: A $145 million annual net loss barely improved from $152 million means the burn is structural, and the equity has nearly tripled on TSR to $195.29 without the loss narrowing - a valuation carried by expectation rather than results. The proxy also describes a share-price mechanic keyed to a seven-day VWAP with a $7.41 reference floor, so financing terms are already indexed to where the stock trades into the record date.

●What changed:SeaStar Medical Holding Corporation, the successor to LMF Acquisition Opportunities Inc, called its 2026 annual meeting for June 17, 2026 at 10:00 a.m. Mountain Time virtually with no physical meeting, record date April 24, 2026, at which 3,997,002 shares of common stock were outstanding. The company effected a 1-for-10 reverse stock split on January 5, 2026. The Board terminated Chief Financial Officer David Green effective August 14, 2025 and Mr. Messinger began serving as a non-employee fractional Chief Financial Officer in November 2025. Directors Rick J. Why it matters: A float of 3,997,002 shares after a January 2026 1-for-10 reverse split leaves the company with almost no equity base, so any financing is severely dilutive in percentage terms and the stock is structurally illiquid. Running the finance function through a part-time fractional CFO after terminating the incumbent, while losing two directors in the same year, points to a company operating on minimal infrastructure. The LMF trust was released at the de-SPAC.

What changed:Orchestra BioMed Holdings, Inc., the successor to Health Sciences Acquisitions Corp 2, called its 2026 annual meeting for Tuesday, June 23, 2026 at 12:00 p.m. Eastern Time, held virtually, with a record date of April 28, 2026 fixed by the board. Materials including the 2025 Annual Report on Form 10-K are available free of charge at proxyvote.com. The compensation section discloses a clawback on Mr. Why it matters: Routine post-de-SPAC annual governance - the HSAQ 2 trust was released at closing, so no redemption right, deadline or per-share floor remains for legacy SPAC holders. The only forward-looking item is the May 15, 2026 bonus repayment cliff, which is a retention lock expiring within weeks of the meeting and therefore a date to watch for executive departures.

●What changed:Calidi Biotherapeutics, Inc., the successor to First Light Acquisition Group, called its annual meeting for Friday, June 12, 2026 at 10:00 a.m. Pacific Time in a completely virtual format, record date April 17, 2026. Holders are asked to approve a charter amendment allowing the Board, at its discretion, to effect a reverse stock split of the Voting and Non-Voting Common Stock at a ratio between 1-for-2 and 1-for-16. Dr. Eric Poma was appointed Chief Executive Officer and director effective April 22, 2025, previously CEO of Molecular Templates. Mr. Why it matters: A split range as wide as 1-for-2 to 1-for-16 hands the board latitude to compress the share count by up to 94%, with the ratio chosen after the vote - holders approve the outcome without knowing it. Paying a director or officer a percentage fee for personally guaranteeing the company's lease is an unusual related-party arrangement that transfers cash to an insider annually. The First Light trust was released at the de-SPAC.

What changed:Amprius Technologies, Inc., successor to Kensington Capital Acquisition Corp. IV, noticed its annual meeting for June 11, 2026 at 10:00 am local time by live audio webcast, record date April 13, 2026, with items including auditor ratification for the fiscal year ending December 31, 2026. Thomas M. Stepien was appointed Chief Executive Officer effective January 1, 2026 after Dr. Kang Sun stepped down as CEO effective December 31, 2025 and became Executive Advisor. Why it matters: The warrant structure is the investor-relevant detail carried over from the Kensington IV SPAC: PIPE Warrants sit outside any exchange listing and cannot be called until the stock averages above $20.00, versus $18.00 for public warrants, so that block stays outstanding as dilution far longer than the listed paper. The CEO handover effective January 1, 2026 puts a new executive in place for the first full year under those terms.

What changed:AEON Biopharma, Inc., the successor to Priveterra Acquisition Corp., called its 2026 annual meeting for Wednesday, June 17, 2026 at 10:00 a.m. Pacific Time in person at its Irvine, California offices, record date April 21, 2026, at which 26,307,211 shares of Class A Common Stock were outstanding, with 33.34% of voting power required for quorum. Robert Bancroft signs as President and Chief Executive Officer. Why it matters: Routine annual governance for a clinical-stage company whose Priveterra trust was released at the de-SPAC, so the 26.3 million Class A shares carry no floor. The item worth tracking is leadership continuity: a chief executive resigned in spring 2025 with related chairman-level disclosure days later, and the successor faces holders for the first time here. A 33.34% quorum bar means outcomes turn on a modest share of the register.

What changed:Terrestrial Energy Inc., the successor to HCM II Acquisition Corp., called its 2026 annual meeting for Thursday, June 11, 2026 at 10:00 a.m. Eastern time solely by remote communication, record date April 20, 2026, with holders of both common stock and special voting preferred stock entitled to vote. Holders elect three Class I directors to three-year terms expiring in 2029 and ratify UHY LLP for the fiscal year ending December 31, 2026. Why it matters: This is the first annual meeting after the October 28, 2025 closing, so the HCM II trust is released and no redemption right survives. Special voting preferred stock voting alongside common preserves a separate control block from the de-SPAC structure. The redeemable warrants exercisable at $11.50 set the level above which that dilution converts, and reverse-recapitalization accounting means the historical financials are TEDI's, not the SPAC's.

●What changed:XBP Global Holdings, Inc., the successor to CF Acquisition Corp. VIII, noticed a virtual annual meeting for May 29, 2026 at 1:00 p.m. ET at virtualshareholdermeeting.com/XBP2026, to elect seven director nominees among other items, with materials first mailed on or about April 29, 2026. The proxy discloses that on December 12, 2025 the company effected a reverse stock split under which every ten shares of common stock outstanding were automatically combined into one. Effective July 29, 2025, Messrs. Akins and Clark resigned from the Board and Mr. Klein, Ms. Paolillo, Mr. Pryor and Mr. Why it matters: A 1-for-10 reverse split executed December 12, 2025 is the standard cure for an exchange minimum-price deficiency, and it tells holders the pre-split stock had fallen below listing thresholds. Combined with four board seats turning over on a single date in July 2025, this is a company that has been reconstituted rather than one executing a stable post-de-SPAC plan; the CF VIII trust was released long before and offers no floor.

●What changed:LanzaTech Global, Inc., the successor to AMCI Acquisition Corp. II, called its 2026 annual meeting for Tuesday, June 23, 2026, record date April 28, 2026, with 10,089,163 shares of common stock issued and outstanding and entitled to one vote each. Holders elect two Class III directors to terms expiring in 2029 and ratify BDO USA, P.C. for the fiscal year ending December 31, 2026. Why it matters: Two consecutive audit opinions carrying substantial-doubt going-concern language is the material fact - the company is asking holders to ratify an auditor that has twice qualified its viability. With only 10,089,163 shares outstanding, any rescue financing at these levels would dilute existing holders severely, and the AMCI trust that once backed the stock was released at the de-SPAC, so there is no cash floor beneath the equity.

What changed:OmniAb, Inc., the successor to Avista Public Acquisition Corp. II, called its 2026 annual meeting for Wednesday, June 17, 2026 at 8:00 a.m. Pacific Time, held in person at the company's headquarters at 5980 Horton Street, Suite 600, Emeryville, California, record date April 23, 2026. The related-party disclosure covers Avista entities including ACP V Offshore and options to purchase 40,000 shares of common stock issued to former director Joshua Tamaroff, who on resignation assigned all rights to an Avista affiliate controlled by Mr. Dean and Mr. Burgstahler. Why it matters: Unusually for this cohort the meeting is held in person rather than virtually, which raises the practical bar for retail participation. The substantive item is that the SPAC sponsor's economics persist post-deal: sponsor warrants that the company cannot redeem in any scenario, plus director options reassigned to an Avista affiliate on resignation, leave the original sponsor group holding non-callable dilution against public holders indefinitely.

●What changed:Definitive proxy statement (DEF 14A) soliciting shareholder votes on a charter amendment to extend the business combination deadline from June 16, 2026 to June 16, 2027, and an adjournment proposal. The company proposes a charter amendment that would extend the termination date by 12 months without requiring any additional deposits into the trust account. Under the current charter, extensions require $550,000 per three-month period from the sponsor. The sponsor has stated it does not plan to make such deposits. The proposed amended charter eliminates that funding requirement, meaning the trust account will not be replenished, and non-redeeming shareholders will receive less in any subsequent redemption or liquidation. The redemption deadline for this meeting is May 15, 2026 (two business days before the May 19 meeting). As of April 10, 2026, the trust held approximately $56.7 million, implying a per-share redemption price of about $10.31 if no further redemptions occur before the calculation date. Why it matters: This filing is critical because it directly affects redemption mechanics and trust value preservation. Shareholders must decide whether to redeem now (at an estimated ~$10.31) or risk a lower payout later if the extension passes without sponsor contributions. The sponsor's refusal to fund extensions signals possible financial strain or lack of commitment, increasing the risk of eventual liquidation with diminished trust proceeds. The filing also confirms that a merger agreement with HDEducation Group Limited is in place but requires regulatory approvals (CSRC and SEC) that may not be completed by the current deadline. Investors tracking deal progress and sponsor conduct should note the explicit disclosure that the amended charter would dilute trust value for non-redeeming holders.

What changed:Hims & Hers Health, Inc., the successor to Oaktree Acquisition Corp., called its 2026 annual meeting for Thursday, June 11, 2026 at 11:00 a.m. Pacific Time virtually, record date April 15, 2026, electing nine directors to serve until 2027. Fiscal 2025 results disclosed are total revenue of $2.35 billion, up 59% year over year; 2.5 million subscribers at year end, up 13%; net income of $128.4 million against $126.0 million in fiscal 2024; Adjusted EBITDA of $318.0 million; and operating cash flow of $300.0 million. Why it matters: Revenue of $2.35 billion growing 59% with $128.4 million of GAAP net income and $300.0 million of operating cash flow makes Hims & Hers one of the few de-SPAC successors generating substantial real cash - the Oaktree trust financed a business that now funds itself. Free cash flow of $57 million is far below operating cash flow, so capital spending absorbs most of it, and annual one-year director terms give holders full board accountability each year.

●What changed:AST SpaceMobile, Inc., the successor to New Providence Acquisition Corp., called its 2026 annual meeting for Friday, June 12, 2026 at 10:00 a.m. ET by live webcast, with registration at proxydocs.com/ASTS required before 9:30 a.m. that day and a record date of April 22, 2026. The proxy discloses that Rakuten Mobile no longer holds a sufficient percentage of Class A Common Stock to retain its director designation right under the Stockholders' Agreement, and accordingly its prior designee Mr. Why it matters: Two strategic holders falling below their designation thresholds means Rakuten Mobile and Antares have diluted down or sold - a signal about anchor-investor conviction, and it removes their board representation and the oversight that came with it. The proxy also warns that where the company relies on governance exemptions, Class A holders will not have the same protections as shareholders of companies subject to all Nasdaq requirements.

●What changed:Faraday Future Intelligent Electric Inc. called its 2026 annual meeting for May 22, 2026 at 9:00 a.m. Pacific Time, record date April 15, 2026, with materials mailed on or about April 28, 2026. Proposals include Nasdaq Rule 5635(d) approvals for issuing Class A Common Stock to the holder of promissory notes and to the holder of preferred shares, a Share Authorization Proposal raising authorised Common and Preferred Stock from 336,372,704 to 487,740,421 shares, a reverse stock split of up to 1-for-150 at the board's discretion, and a Third Amended and Restated 2021 Stock Incentive Plan. Why it matters: A reverse split of up to 1-for-150 combined with raising authorised capital to 487,740,421 shares would leave the company able to issue vastly more stock than the compressed post-split base - the classic structure for continuous dilutive financing. Two separate Nasdaq 20% Rule votes, one for note holders and one for preferred holders, confirm that both debt and preferred are being converted into common. Holders approving all of it authorise essentially unlimited future issuance.

What changed:Verde Clean Fuels, Inc., the successor to CENAQ Energy Corp, called its 2026 annual meeting for Friday, June 12, 2026 at 10:00 a.m. ET by live webcast, record date April 24, 2026. At that date there were 44,549,621 shares outstanding, comprising 22,049,621 shares of Class A common stock and 22,500,000 shares of Class C common stock. Holders vote to re-elect Jonathan Siegler as the sole Class III director to serve until 2029 and to ratify Deloitte & Touche LLP for the fiscal year ending December 31, 2026. Mr. Why it matters: The capital structure is effectively split down the middle - 22,500,000 Class C shares against 22,049,621 Class A - so the legacy sponsor and rollover holders control slightly more than half the vote and public Class A holders cannot carry a proposal alone. The executive severance language contemplating a wind down of the Company, and a milestone tied to reaching a notice to proceed on a facility, are drafted for a scenario in which the project does not advance.

●What changed:Opendoor Technologies Inc., the successor to Social Capital Hedosophia Holdings Corp. II, called its 2026 annual meeting for Thursday, June 11, 2026 at 9:30 a.m. Pacific Time online only, record date April 16, 2026, at which 964,704,409 shares of Common Stock were outstanding with one vote each. Mr. Nejatian was appointed Chief Executive Officer effective September 10, 2025, succeeding Mr. Radhakrishna who had served as President and interim Principal Executive Officer since August 15, 2025 after the previous CEO resigned. Mr. Why it matters: An inducement award of 40,886,344 performance RSUs to a single executive is roughly 4% of the 964.7 million shares outstanding - one of the largest individual equity grants in this cohort, and granted as an inducement so it sits outside the shareholder-approved plan. Three chief executives within a single year signals instability at the top of a company already carrying near-billion-share dilution. Make-whole TRSUs accelerate on an involuntary termination.

What changed:Grove Collaborative Holdings, Inc., the Delaware public benefit corporation successor to Virgin Group Acquisition Corp. II, noticed its 2026 annual meeting for Thursday, June 18, 2026 at 8:00 a.m. Pacific Time as a virtual meeting, record date April 24, 2026, with 42,028,075 shares outstanding on that date. Business is director elections and ratification of the auditor for the year ending December 31, 2026. Why it matters: Standard annual governance with no trust or redemption mechanic surviving from the VGAC II SPAC. The item for common holders is the Series A Preferred sitting in the capital structure on a pari passu basis - preferred capital raised after the de-SPAC that ranks ahead of or alongside the 42.0 million common shares in a distribution, so common recovery in any strategic outcome is measured after that stack.

●What changed:WM Technology, Inc., the successor to Silver Spike Acquisition Corp., called its annual meeting for Wednesday, June 24, 2026 at 10:00 a.m. Pacific Time by live audio webcast, record date Monday, April 27, 2026. Critically, the proxy discloses that on April 7, 2026 the company gave notice of its voluntary intention to delist its Class A Common Stock and Warrants from the Nasdaq Global Select Market and to eventually deregister both under the Exchange Act, and that it made the corresponding SEC filing on April 17, 2026. Why it matters: A voluntary delisting and deregistration is the single most consequential outcome for a public holder short of liquidation: the Class A shares and warrants lose their Nasdaq market, and deregistration ends Exchange Act reporting, so holders lose both liquidity and the disclosure stream. The April 7 notice and April 17, 2026 filing mean this is already in motion and is not being put to the June 24 vote - shareholders are being noticed, not asked.

What changed:AdaptHealth Corp., the successor to DFB Healthcare Acquisitions Corp., noticed its annual meeting for June 18, 2026, record date April 24, 2026, with three items: director elections, ratification of the independent registered public accounting firm for the fiscal year ending December 31, 2026, and a non-binding advisory say-on-pay vote. Why it matters: Routine annual governance with no trust or redemption right remaining from the DFB SPAC. The structural residue worth noting is that a board designation right granted to the BlueMountain Entities in November 2019, before the de-SPAC, still governs board composition, and the BM Notes remain part of the defined capital structure - legacy sponsor-era agreements that continue to allocate board seats independently of the shareholder vote being solicited here.

What changed:AerSale Corporation, the successor to Monocle Acquisition Corp, called its 2026 annual meeting for Thursday, June 11, 2026 at 10:30 a.m. Eastern time as a fully virtual webcast, record date April 21, 2026, with 47,252,829 shares of common stock outstanding. The financial highlights report that revenue decreased approximately 2.8% to $335.3 million in 2025 from $345.1 million in 2024, while net income increased approximately 46.6% to $8.6 million from $5.9 million. Board committee changes are disclosed, including Mr. Why it matters: Net income up 46.6% to $8.6 million on revenue down 2.8% to $335.3 million shows margin expansion rather than growth - the company is earning more on a smaller base. For a de-SPAC successor that is a durable position: profitability at this level against 47.3 million shares means no financing pressure and no dependence on issuing stock, which separates AerSale from most of the Monocle-era cohort.

What changed:BigBear.ai Holdings, Inc. called its annual meeting for Tuesday, June 9, 2026 at 2:00 p.m. ET, virtual at virtualshareholdermeeting.com/BBAI2026AGM, record date April 13, 2026, with materials delivered on or about April 28, 2026. Quorum under the bylaws is one-third, or 33.33%, of the voting power outstanding. Unvested PSU values are calculated at the NYSE closing price of $5.40 per share on December 31, 2025. Ms. Peffer's PSUs were forfeited on her departure June 6, 2025 with her target annual bonus paid in cash under the Executive Severance Plan; Ms. Why it matters: A one-third quorum threshold means proposals can pass on a thin turnout, which matters for a widely held retail name. The disclosed executive churn is the substantive signal: a CFO departure in June 2025 and another senior termination in January 2025, both with severance triggered, against a $5.40 December 31, 2025 reference price that anchors every outstanding equity award. No SPAC trust or redemption right remains.

●What changed:Humacyte, Inc., the successor to Alpha Healthcare Acquisition Corp., called its annual meeting for June 9, 2026 at 8:00 a.m. Eastern Time in a virtual-only format, record date April 23, 2026, electing John P. Bamforth, Keith Anthony Jones and others as directors. RSU values are struck at the last reported closing price of $0.96 on Nasdaq as of December 31, 2025. The pay-versus-performance table reports a 2025 net loss of $40,833,184 with total shareholder return of $33.80 per $100 invested, against a 2024 net loss of $148,701,234 and TSR of $177.82. Why it matters: A $0.96 share price at December 31, 2025 puts the Nasdaq $1.00 minimum bid requirement immediately in play, and total shareholder return collapsed from $177.82 to $33.80 in a single year - an 81% decline. The net loss narrowed sharply to $40.8 million from $148.7 million, so the burn is being contained, but at a sub-dollar price further equity financing would be heavily dilutive. The Alpha Healthcare trust was released at the de-SPAC.

What changed:BridgeBio Oncology Therapeutics, Inc. (BBOT), the successor to Helix Acquisition Corp. II, called its 2026 annual meeting for Tuesday, June 16, 2026 at 1:00 p.m. Pacific Daylight Time, virtual, record date April 20, 2026, with 80,112,725 shares of common stock outstanding. Holders elect two Class I directors to serve until 2029 and ratify Deloitte & Touche LLP for the fiscal year ending December 31, 2026. Helix consummated the business combination on August 11, 2025 under a business combination agreement dated February 28, 2025 and amended June 17, 2025. Why it matters: This is the first annual meeting after the August 11, 2025 closing, so the Helix II trust has been released and no redemption right or per-share floor survives for legacy SPAC holders. From here the 80.1 million shares are backed only by the oncology pipeline; the amended-then-closed deal timeline shows the transaction required renegotiation four months before closing, which is worth remembering when reading later disclosure about deal terms.

What changed:Clover Health Investments, Corp., the successor to Social Capital Hedosophia Holdings Corp. III (IPOC), noticed its 2026 annual meeting for June 10, 2026 at 11:00 a.m. ET as a virtual-only meeting at virtualshareholdermeeting.com/CLOV2026, record date April 15, 2026. Holders vote on director elections, 2025 named executive officer compensation and ratification of Ernst & Young LLP. The proxy discloses that Clay Thornton was appointed Interim Chief Financial Officer effective March 30, 2026, succeeding Mr. Peter Kuipers, and lists Conrad Wai as Chief Executive Officer of Counterpart Health. Why it matters: An interim rather than permanent CFO appointment effective March 30, 2026, weeks before the proxy was filed, leaves the finance function unsettled going into the meeting - a governance risk for a regulated insurer whose reporting quality drives its rating. Otherwise this is routine annual business; the IPOC trust was released years ago and legacy SPAC holders retain no redemption right or per-share floor.

What changed:OppFi Inc., the successor to FG New America Acquisition Corp., noticed its 2026 annual meeting for Tuesday, June 9, 2026 at 1:30 p.m. Central Time (2:30 p.m. Eastern) as a virtual webcast requiring registration at proxydocs.com/OPFI, record date April 21, 2026. At the record date there were 26,739,319 shares of Class A Common Stock and 58,638,241 shares of Class V Common Stock outstanding, each carrying one vote. The board is divided into three staggered classes. The proxy references the Business Combination Agreement dated February 9, 2021 among the Company, OppFi-LLC and OppFi Shares, LLC. Why it matters: Class V holders control 58.6 million of the roughly 85.4 million total votes - about 69% - so the public Class A block of 26.7 million shares cannot determine any outcome at this meeting, including the say-on-pay vote. Combined with a staggered three-class board that limits turnover to one class a year, minority holders have essentially no mechanism to force change, which is the enduring legacy of the FG New America deal structure.

What changed:Ouster, Inc., the successor to Colonnade Acquisition Corp., noticed its 2026 annual meeting for Wednesday, June 17, 2026 at 10:00 a.m. Pacific Time as a completely virtual meeting, record date April 24, 2026, with 63,672,949 shares of common stock issued and outstanding and entitled to vote. The pay-versus-performance table reports a 2025 net loss of $60,377 thousand against $97,045 thousand in 2024, with total shareholder return rising to $250.75 per $100 invested from $141.60. Cyrille Jacquemet was appointed an executive officer on April 12, 2026. Why it matters: The net loss narrowed by 38% to $60.4 million while total shareholder return rose to $250.75 per $100 - improvement on both sides, unusual in this cohort where TSR recoveries usually run ahead of unchanged losses. Against 63.7 million shares outstanding the remaining $60.4 million annual burn still implies future capital needs, so the trajectory rather than the level is what supports the equity; the Colonnade trust offers no floor.

What changed:Disc Medicine, Inc., the successor to FS Development Corp., called its 2026 annual meeting for June 18, 2026, record date April 22, 2026, with 38,199,089 shares of common stock outstanding and entitled to vote. Holders elect Class III directors among other items. The pay-versus-performance table reports a 2025 net loss of $212,184 thousand against $109,357 thousand in 2024, with total shareholder return rising to $257.82 per $100 invested from $205.84 while the peer group returned $119.85. The compensation committee met three times during the year ended December 31, 2025. Why it matters: The net loss nearly doubled to $212.2 million in 2025 while total shareholder return climbed to $257.82 and outran a $119.85 peer group - the equity is being priced on clinical expectation rather than results, and a burn of that size against 38.2 million shares outstanding implies substantial future financing. Legacy FS Development trust holders have no floor here; the downside is the pipeline, not a redemption price.

What changed:Butterfly Network, Inc., the successor to Longview Acquisition Corp., called its 2026 annual meeting for Thursday, June 18, 2026 at 11:00 a.m. Eastern Time solely by live audio webcast, record date April 21, 2026, with Notice of Internet Availability sent on or about April 27, 2026. Beneficial ownership is based on 234,777,441 shares of Class A and 26,426,937 shares of Class B common stock outstanding as of April 1, 2026. Ms. Getz resigned as Chief Financial and Operations Officer on August 1, 2025 and departed August 15, 2025, continuing as an adviser through year end; Mr. Why it matters: Class B shares of 26.4 million against a 234.8 million Class A float preserve founder voting weight from the November 2020 business combination, so the public block does not control outcomes. The departure of the combined chief financial and operations officer in August 2025 removes two functions from one seat at once. The Longview trust was released at the de-SPAC, so the equity depends on device commercialisation alone.

●What changed:Alight, Inc., the successor to Foley Trasimene Acquisition Corp. (WPF), called its 2026 annual meeting for June 10, 2026 at 1:00 p.m. Central Time by live webcast, record date April 22, 2026. Beyond routine items, stockholders are asked to approve reverse stock splits at ratios between 1-for-30 and 1-for-40, with corresponding decreases in authorized shares. The company has two classes of voting common stock, Class A and Class V, each with one vote per share. The FTAC business combination with Alight Holding Company, LLC closed July 2, 2021. Why it matters: A proposed reverse split as deep as 1-for-40 is an order of magnitude beyond the usual 1-for-10 listing cure, and it implies the stock trades at a small fraction of a dollar. Authorized shares fall in step, so this is a genuine recapitalization rather than a pure listing fix. For legacy Foley Trasimene holders it marks the end point of a 2021 de-SPAC: no trust remains, and the share count is about to be compressed by up to 97.5%.